Tetramer-guided	O
epitope	O
mapping	O
:	O
rapid	O
identification	O
and	O
characterization	O
of	O
immunodominant	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cell	I-cell_type
epitopes	I-cell_type
from	O
complex	O
antigens	B-protein
.	O

T	O
cell	O
responses	O
to	O
Ags	B-protein
involve	O
recognition	O
of	O
selected	O
peptide	B-protein
epitopes	I-protein
contained	O
within	O
the	O
antigenic	B-protein
protein	I-protein
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
a	O
new	O
approach	O
for	O
direct	O
identification	O
of	O
CD4+	B-cell_type
T	I-cell_type
cell	I-cell_type
epitopes	I-cell_type
of	O
complex	O
Ags	B-protein
that	O
uses	O
human	B-protein
class	I-protein
II	I-protein
tetramers	I-protein
to	O
identify	O
reactive	O
cells	O
.	O

With	O
a	O
panel	O
of	O
60	O
overlapping	O
peptides	O
covering	O
the	O
entire	O
sequence	O
of	O
the	O
VP16	B-protein
protein	I-protein
,	O
a	O
major	O
Ag	B-protein
for	O
HSV-2	O
,	O
we	O
generated	O
a	O
panel	O
of	O
class	B-protein
II	I-protein
MHC	I-protein
tetramers	I-protein
loaded	O
with	O
peptide	O
pools	O
that	O
were	O
used	O
to	O
stain	O
peripheral	B-cell_type
lymphocytes	I-cell_type
of	O
an	O
HSV-2	O
infected	O
individual	O
.	O

With	O
this	O
approach	O
,	O
we	O
identified	O
four	O
new	O
DRA1*0101/DRB1*0401-	O
and	O
two	O
DRA1*0101/DRB1*0404-restricted	O
,	O
VP16-specific	B-protein
epitopes	I-protein
.	O

By	O
using	O
tetramers	B-protein
to	O
sort	O
individual	O
cells	O
,	O
we	O
easily	O
obtained	O
a	O
large	O
number	O
of	O
clones	O
specific	O
to	O
these	O
epitopes	B-protein
.	O

Although	O
DRA1*0101/DRB1*0401	O
and	O
DRA1*0101/DRB1*0404	O
are	O
structurally	O
very	O
similar	O
,	O
nonoverlapping	O
VP16	B-protein
epitopes	I-protein
were	O
identified	O
,	O
illustrating	O
high	O
selectivity	O
of	O
individual	O
allele	O
polymorphisms	O
within	O
common	O
MHC	O
variants	O
.	O

This	O
rapid	O
approach	O
to	O
detecting	O
CD4+	B-cell_type
T	I-cell_type
cell	I-cell_type
epitopes	I-cell_type
from	O
complex	O
Ags	B-protein
can	O
be	O
applied	O
to	O
any	O
known	O
Ag	B-protein
that	O
gives	O
a	O
T	O
cell	O
response	O
.	O

)	NULL
&	NULL
_-	NULL
.	NULL

_	NULL
The	NULL
Attune	NULL
``	NULL
NXT	NULL
Flow	NULL
Cytometer	NULL
system	NULL
-	NULL
-	NULL
Let	NULL
's	NULL
get	NULL
to	NULL
the	NULL
science	NULL
e	NULL
E°	NULL
``	NULL
invitrogen	NULL
Tetramer-Guided	NULL
Epitope	NULL
Mapping	NULL
:	NULL
Rapid	NULL
f	NULL
-	NULL
<	NULL
The	NULL
10	NULL
leﬁrijllgﬁzhélo	NULL
gy	NULL
Identification	NULL
and	NULL
Characterization	NULL
of	NULL
Immunodominant	NULL
CD4*	NULL
T	NULL
Cell	NULL
Epitopes	NULL
from	NULL
Complex	NULL
Antigens	NULL
This	NULL
information	NULL
is	NULL
current	NULL
as	NULL
of	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Erik	NULL
J.	NULL
Novak	NULL
,	NULL
Andrew	NULL
W.	NULL
Liu	NULL
,	NULL
John	NULL
A.	NULL
Gebe	NULL
,	NULL
Ben	NULL
A.	NULL
Falk	NULL
,	NULL
Gerald	NULL
T.	NULL
Nepom	NULL
,	NULL
David	NULL
M.	NULL
Koelle	NULL
and	NULL
William	NULL
W.	NULL
Kwok	NULL
J	NULL
Immunol	NULL
2001	NULL
;	NULL
166:6665-6670	NULL
;	NULL
;	NULL
doi	NULL
:	NULL
10.4049/jimmunol.166.11.6665	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/166/11/6665	NULL
References	NULL
_	NULL
This	NULL
article	NULL
cites	NULL
38	NULL
articles	NULL
,	NULL
19	NULL
of	NULL
which	NULL
you	NULL
can	NULL
access	NULL
for	NULL
free	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/166/11/6665	NULL
.	NULL

full	NULL
#	NULL
ref-list-	NULL
1	NULL
Why	NULL
The	NULL
JT	NULL
?	NULL

Submit	NULL
online	NULL
.	NULL

«	NULL
Rapid	NULL
Reviews	NULL
!	NULL

30	NULL
days*	NULL
from	NULL
submission	NULL
to	NULL
initial	NULL
decision	NULL
*	NULL
No	NULL
Triage	NULL
!	NULL

Every	NULL
submission	NULL
reviewed	NULL
by	NULL
practicing	NULL
scientists	NULL
*	NULL
Fast	NULL
Publication	NULL
!	NULL

4	NULL
weeks	NULL
from	NULL
acceptance	NULL
to	NULL
publication	NULL
*average	NULL
Subscription	NULL
_-	NULL
Information	NULL
about	NULL
subscribing	NULL
to	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/subscription	NULL
Permissions	NULL
_	NULL
Submit	NULL
copyright	NULL
permission	NULL
requests	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.aai.org/About/Publications/Jl/copyright.html	NULL
Email	NULL
Alerts	NULL
_	NULL
Receive	NULL
free	NULL
email-alerts	NULL
when	NULL
new	NULL
articles	NULL
cite	NULL
this	NULL
article	NULL
.	NULL

Sign	NULL
up	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/alerts	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
published	NULL
twice	NULL
each	NULL
month	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
,	NULL
Inc.	NULL
,	NULL
1451	NULL
Rockville	NULL
Pike	NULL
,	NULL
Suite	NULL
650	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
20852	NULL
Copyright	NULL
©	NULL
2001	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
All	NULL
rights	NULL
reserved	NULL
.	NULL

Print	NULL
ISSN	NULL
:	NULL
0022-1767	NULL
Online	NULL
ISSN	NULL
:	NULL
1550-6606	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
Tetramer-Guided	NULL
Epitope	NULL
Mapping	NULL
:	NULL
Rapid	NULL
Identification	NULL
and	NULL
Characterization	NULL
of	NULL
Immunodominant	NULL
CD4*	NULL
T	NULL
Cell	NULL
Epitopes	NULL
from	NULL
Complex	NULL
Antigens	NULL
Erik	NULL
J.	NULL
Novak	NULL
,	NULL
*	NULL
``	NULL
Andrew	NULL
W.	NULL
Liu	NULL
,	NULL
*	NULL
John	NULL
A.	NULL
Gebe	NULL
,	NULL
*	NULL
Ben	NULL
A.	NULL
Falk	NULL
,	NULL
*	NULL
Gerald	NULL
T.	NULL
Nepom	NULL
,	NULL
*	NULL
David	NULL
M.	NULL
Koelle	NULL
,	NULL
**	NULL
and	NULL
William	NULL
W.	NULL
Kwok**	NULL
T	NULL
cell	NULL
responses	NULL
to	NULL
Ags	NULL
involve	NULL
recognition	NULL
of	NULL
selected	NULL
peptide	NULL
epitopes	NULL
contained	NULL
within	NULL
the	NULL
antigenic	NULL
protein	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
describe	NULL
a	NULL
new	NULL
approach	NULL
for	NULL
direct	NULL
identification	NULL
of	NULL
CD4*	NULL
T	NULL
cell	NULL
epitopes	NULL
of	NULL
complex	NULL
Ags	NULL
that	NULL
uses	NULL
human	NULL
class	NULL
II	NULL
tetramers	NULL
to	NULL
identify	NULL
reactive	NULL
cells	NULL
.	NULL

With	NULL
a	NULL
panel	NULL
of	NULL
60	NULL
overlapping	NULL
peptides	NULL
covering	NULL
the	NULL
entire	NULL
sequence	NULL
of	NULL
the	NULL
VP16	NULL
protein	NULL
,	NULL
a	NULL
major	NULL
Ag	NULL
for	NULL
HSV-2	NULL
,	NULL
we	NULL
generated	NULL
a	NULL
panel	NULL
of	NULL
class	NULL
II	NULL
MHC	NULL
tetramers	NULL
loaded	NULL
with	NULL
peptide	NULL
pools	NULL
that	NULL
were	NULL
used	NULL
to	NULL
stain	NULL
peripheral	NULL
lymphocytes	NULL
of	NULL
an	NULL
HSV-2	NULL
infected	NULL
individual	NULL
.	NULL

With	NULL
this	NULL
approach	NULL
,	NULL
we	NULL
identified	NULL
four	NULL
new	NULL
DRA1*0101/DRB1*0401-	NULL
and	NULL
two	NULL
DRA1*0101/	NULL
DRB1*0404-restricted	NULL
,	NULL
VP16-specific	NULL
epitopes	NULL
.	NULL

By	NULL
using	NULL
tetramers	NULL
to	NULL
sort	NULL
individual	NULL
cells	NULL
,	NULL
we	NULL
easily	NULL
obtained	NULL
a	NULL
large	NULL
number	NULL
of	NULL
clones	NULL
specific	NULL
to	NULL
these	NULL
epitopes	NULL
.	NULL

Although	NULL
DRA1*0101/DRB1*0401	NULL
and	NULL
DRA1*0101/DRB1*0404	NULL
are	NULL
structurally	NULL
very	NULL
similar	NULL
,	NULL
nonoverlapping	NULL
VP16	NULL
epitopes	NULL
were	NULL
identified	NULL
,	NULL
illustrating	NULL
high	NULL
selectivity	NULL
of	NULL
individual	NULL
allele	NULL
polymorphisms	NULL
within	NULL
common	NULL
MHC	NULL
variants	NULL
.	NULL

This	NULL
rapid	NULL
approach	NULL
to	NULL
detecting	NULL
CD4*	NULL
T	NULL
cell	NULL
epitopes	NULL
from	NULL
complex	NULL
Ags	NULL
can	NULL
be	NULL
applied	NULL
to	NULL
any	NULL
known	NULL
Ag	NULL
that	NULL
gives	NULL
a	NULL
T	NULL
cell	NULL
response	NULL
.	NULL

The	NULL
Journal	NULL
of	NULL
Immunology	NULL
,	NULL
2001	NULL
,	NULL
166	NULL
:	NULL
6665-6670.	NULL
ognition	NULL
of	NULL
selected	NULL
peptide	NULL
epitopes	NULL
presented	NULL
in	NULL
the	NULL
con	NULL
text	NULL
of	NULL
MHC	NULL
molecules	NULL
expressed	NULL
on	NULL
APCs	NULL
.	NULL

The	NULL
choice	NULL
of	NULL
these	NULL
immunogenic	NULL
epitopes	NULL
from	NULL
among	NULL
the	NULL
often	NULL
hundreds	NULL
or	NULL
thousands	NULL
of	NULL
amino	NULL
acids	NULL
comprising	NULL
an	NULL
antigenic	NULL
protein	NULL
depends	NULL
significantly	NULL
on	NULL
the	NULL
binding	NULL
properties	NULL
of	NULL
a	NULL
given	NULL
MHC	NULL
type	NULL
and	NULL
the	NULL
interactions	NULL
of	NULL
specific	NULL
amino	NULL
acids	NULL
with	NULL
the	NULL
TCR	NULL
.	NULL

Understanding	NULL
which	NULL
peptide	NULL
epitopes	NULL
participate	NULL
in	NULL
T	NULL
cell-mediated	NULL
immunity	NULL
provides	NULL
a	NULL
basis	NULL
for	NULL
directed	NULL
modulation	NULL
of	NULL
the	NULL
immune	NULL
re-sponse	NULL
,	NULL
including	NULL
development	NULL
of	NULL
peptide	NULL
vaccines	NULL
and	NULL
therapies	NULL
against	NULL
allergens	NULL
,	NULL
autoimmune	NULL
diseases	NULL
and	NULL
tumors	NULL
(	NULL
1-5	NULL
)	NULL
.	NULL

However	NULL
,	NULL
elucidation	NULL
of	NULL
specific	NULL
epitopes	NULL
from	NULL
complex	NULL
Ags	NULL
can	NULL
be	NULL
a	NULL
cumbersome	NULL
and	NULL
difficult	NULL
process	NULL
,	NULL
as	NULL
it	NULL
generally	NULL
involves	NULL
extensive	NULL
phenotype	NULL
screening	NULL
of	NULL
T	NULL
cell	NULL
clones	NULL
isolated	NULL
from	NULL
whole	NULL
Ag-stimulated	NULL
cells	NULL
.	NULL

A	NULL
number	NULL
of	NULL
recent	NULL
studies	NULL
have	NULL
used	NULL
soluble	NULL
MHC	NULL
multimers	NULL
to	NULL
directly	NULL
identify	NULL
T	NULL
cells	NULL
restricted	NULL
to	NULL
specific	NULL
peptide	NULL
epitopes	NULL
.	NULL

This	NULL
technology	NULL
has	NULL
been	NULL
used	NULL
to	NULL
track	NULL
T	NULL
cells	NULL
specific	NULL
for	NULL
both	NULL
viral	NULL
Ags	NULL
(	NULL
6-9	NULL
)	NULL
and	NULL
tumor	NULL
Ags	NULL
(	NULL
10-13	NULL
)	NULL
in	NULL
both	NULL
animal	NULL
models	NULL
and	NULL
in	NULL
humans	NULL
when	NULL
the	NULL
peptide	NULL
epitope	NULL
is	NULL
known	NULL
.	NULL

The	NULL
majority	NULL
of	NULL
these	NULL
studies	NULL
have	NULL
focused	NULL
on	NULL
class	NULL
I-restricted	NULL
T	NULL
cells	NULL
,	NULL
as	NULL
initial	NULL
efforts	NULL
in	NULL
producing	NULL
class	NULL
II	NULL
molecules	NULL
were	NULL
hampered	NULL
by	NULL
difficul-	NULL
P	NULL
I	NULL
¥	NULL
he	NULL
T	NULL
cell-mediated	NULL
response	NULL
to	NULL
complex	NULL
Ags	NULL
involves	NULL
rec-	NULL
*Virginia	NULL
Mason	NULL
Research	NULL
Center	NULL
,	NULL
Benaroya	NULL
Research	NULL
Institute	NULL
,	NULL
Seattle	NULL
,	NULL
WA	NULL
98101	NULL
;	NULL
'	NULL
R	NULL
.	NULL

H.	NULL
Williams	NULL
Laboratory	NULL
,	NULL
Molecular	NULL
and	NULL
Cellular	NULL
Biology	NULL
Program	NULL
,	NULL
and	NULL
*Depart-ments	NULL
of	NULL
Medicine	NULL
and	NULL
Laboratory	NULL
Medicine	NULL
,	NULL
University	NULL
of	NULL
Washington	NULL
,	NULL
Seattle	NULL
,	NULL
WA	NULL
98195	NULL
;	NULL
and	NULL
``	NULL
Fred	NULL
Hutchinson	NULL
Cancer	NULL
Research	NULL
Center	NULL
,	NULL
Seattle	NULL
,	NULL
WA	NULL
98109	NULL
Received	NULL
for	NULL
publication	NULL
November	NULL
1	NULL
,	NULL
2000	NULL
.	NULL

Accepted	NULL
for	NULL
publication	NULL
March	NULL
20	NULL
,	NULL
2001	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
adverfisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL
'	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grants	NULL
AI-44443	NULL
(	NULL
to	NULL
W.W.K	NULL
.	NULL
)	NULL

and	NULL
Al-30731	NULL
(	NULL
to	NULL
D.M.K	NULL
.	NULL
)	NULL

,	NULL
the	NULL
M.J.	NULL
Murdock	NULL
Charitable	NULL
Trust	NULL
,	NULL
and	NULL
the	NULL
William	NULL
Randolph	NULL
Hearst	NULL
Foundation	NULL
.	NULL

E.J.N	NULL
.	NULL

was	NULL
supported	NULL
by	NULL
Achievement	NULL
Rewards	NULL
for	NULL
College	NULL
Scientists	NULL
and	NULL
Poncin	NULL
predoctoral	NULL
fellowships	NULL
.	NULL

?	NULL

Address	NULL
correspondence	NULL
and	NULL
reprint	NULL
requests	NULL
to	NULL
Dr.	NULL
William	NULL
W.	NULL
Kwok	NULL
,	NULL
Virginia	NULL
Mason	NULL
Research	NULL
Center	NULL
,	NULL
1201	NULL
Ninth	NULL
Avenue	NULL
,	NULL
Seattle	NULL
,	NULL
WA	NULL
98101-2795	NULL
.	NULL

E-mail	NULL
ad-dress	NULL
:	NULL
bewok	NULL
@	NULL
vmresearch.org	NULL
Copyright	NULL
©	NULL
2001	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
ties	NULL
in	NULL
generating	NULL
stable	NULL
soluble	NULL
forms	NULL
of	NULL
the	NULL
molecules	NULL
and	NULL
inefficiency	NULL
in	NULL
biotinylation	NULL
of	NULL
these	NULL
molecules	NULL
.	NULL

One	NULL
approach	NULL
to	NULL
stabilizing	NULL
the	NULL
soluble	NULL
class	NULL
II	NULL
molecules	NULL
has	NULL
involved	NULL
covalently	NULL
tethering	NULL
the	NULL
peptide	NULL
to	NULL
the	NULL
-chain	NULL
of	NULL
the	NULL
class	NULL
II	NULL
molecule	NULL
(	NULL
14	NULL
,	NULL
15	NULL
)	NULL
.	NULL

However	NULL
,	NULL
tethering	NULL
of	NULL
peptide	NULL
to	NULL
class	NULL
II	NULL
molecules	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
be	NULL
essential	NULL
for	NULL
the	NULL
stability	NULL
of	NULL
soluble	NULL
class	NULL
II	NULL
molecules	NULL
,	NULL
as	NULL
demonstrated	NULL
by	NULL
the	NULL
successful	NULL
detection	NULL
of	NULL
Ag-specific	NULL
T	NULL
cells	NULL
in	NULL
mice	NULL
and	NULL
humans	NULL
by	NULL
using	NULL
soluble	NULL
MHC	NULL
molecules	NULL
with	NULL
exog-enously	NULL
loaded	NULL
peptide	NULL
(	NULL
16-19	NULL
)	NULL
.	NULL

Efficient	NULL
production	NULL
of	NULL
class	NULL
II	NULL
MHC	NULL
tetramers	NULL
containing	NULL
soluble	NULL
peptide	NULL
offers	NULL
the	NULL
potential	NULL
to	NULL
detect	NULL
and	NULL
isolate	NULL
T	NULL
cells	NULL
specific	NULL
to	NULL
Ags	NULL
in	NULL
which	NULL
the	NULL
T	NULL
cell	NULL
epitopes	NULL
are	NULL
not	NULL
previously	NULL
known	NULL
.	NULL

In	NULL
this	NULL
approach	NULL
,	NULL
tetramers	NULL
are	NULL
loaded	NULL
with	NULL
a	NULL
mixture	NULL
of	NULL
overlapping	NULL
peptides	NULL
that	NULL
cover	NULL
the	NULL
entire	NULL
Ag	NULL
.	NULL

These	NULL
tetramers	NULL
then	NULL
are	NULL
used	NULL
to	NULL
identify	NULL
and	NULL
isolate	NULL
epitope-specific	NULL
T	NULL
cells	NULL
from	NULL
PBMC	NULL
that	NULL
have	NULL
been	NULL
stimulated	NULL
with	NULL
the	NULL
whole	NULL
Ag	NULL
.	NULL

With	NULL
this	NULL
approach	NULL
,	NULL
we	NULL
have	NULL
identified	NULL
four	NULL
DRA1*O101/DRB1*0401	NULL
stricted	NULL
T	NULL
cell	NULL
epitopes	NULL
and	NULL
two	NULL
DRA1*0101/DRB1*0404	NULL
(	NULL
DRO404	NULL
)	NULL
-restricted	NULL
T	NULL
cell	NULL
epitopes	NULL
of	NULL
the	NULL
HSV-2	NULL
tegument	NULL
protein	NULL
VP16	NULL
.	NULL

Earlier	NULL
studies	NULL
have	NULL
demonstrated	NULL
that	NULL
VP16	NULL
epitopes	NULL
are	NULL
recognized	NULL
by	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
that	NULL
infiltrate	NULL
genital	NULL
lesions	NULL
in	NULL
individuals	NULL
with	NULL
HSV-2	NULL
infection	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
protein	NULL
serves	NULL
as	NULL
an	NULL
important	NULL
Ag	NULL
in	NULL
the	NULL
natural	NULL
immune	NULL
response	NULL
to	NULL
HSV-2	NULL
virus	NULL
(	NULL
20	NULL
,	NULL
21	NULL
)	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Generation	NULL
of	NULL
DRO401	NULL
and	NULL
DRO404	NULL
tetramers	NULL
The	NULL
construction	NULL
of	NULL
the	NULL
expression	NULL
vectors	NULL
for	NULL
generation	NULL
of	NULL
soluble	NULL
DRO401	NULL
has	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
18	NULL
)	NULL
.	NULL

A	NULL
similar	NULL
approach	NULL
using	NULL
the	NULL
same	NULL
primers	NULL
was	NULL
used	NULL
to	NULL
generate	NULL
the	NULL
DRB1*0404-leucine	NULL
zipper-bioti-nylation	NULL
site	NULL
expression	NULL
vector	NULL
from	NULL
DRB1*0404	NULL
cDNA	NULL
.	NULL

DRB1*0404	NULL
cDNA	NULL
was	NULL
isolated	NULL
from	NULL
the	NULL
EBV-transformed	NULL
B	NULL
lymphoblastoid	NULL
cell	NULL
line	NULL
Bin-40	NULL
,	NULL
and	NULL
was	NULL
a	NULL
gift	NULL
from	NULL
Dr.	NULL
P.	NULL
Gregersen	NULL
(	NULL
North	NULL
Shore	NULL
University	NULL
°	NULL
Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
DRO401	NULL
,	NULL
DRA1*0101/DRB1*0401	NULL
;	NULL
DRO404	NULL
,	NULL
DRA1*0101/DRB1*0404	NULL
;	NULL
TGEM	NULL
,	NULL
tetramer-guided	NULL
epitope	NULL
mapping	NULL
;	NULL
HAsqy_319	NULL
,	NULL
i-fluenza	NULL
A	NULL
hemagglutinin	NULL
protein	NULL
,	NULL
residues	NULL
307-319	NULL
;	NULL
BLS	NULL
,	NULL
DR-transfected	NULL
bare	NULL
lymphocyte	NULL
syndrome	NULL
.	NULL

0022-1767/01/	NULL
$	NULL
02.00	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
6666	NULL
Hospital	NULL
,	NULL
Manhasset	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
a	NULL
chimeric	NULL
cassette	NULL
containing	NULL
the	NULL
extracellular	NULL
coding	NULL
region	NULL
for	NULL
the	NULL
DRB1*0404	NULL
chain	NULL
appended	NULL
to	NULL
the	NULL
acidic	NULL
leucine	NULL
zipper	NULL
motif	NULL
was	NULL
generated	NULL
from	NULL
DRB1*0404	NULL
and	NULL
leucine	NULL
zipper	NULL
cDNA	NULL
by	NULL
using	NULL
the	NULL
PCR-mediated	NULL
splicing	NULL
overlap	NULL
technique	NULL
(	NULL
22	NULL
,	NULL
23	NULL
)	NULL
.	NULL

A	NULL
site-specific	NULL
biotinylation	NULL
sequence	NULL
then	NULL
was	NULL
added	NULL
to	NULL
the	NULL
3	NULL
'	NULL
end	NULL
of	NULL
the	NULL
DRB1*0404/	NULL
leucine	NULL
zipper	NULL
cassette	NULL
.	NULL

The	NULL
chimeric	NULL
cDNA	NULL
was	NULL
subcloned	NULL
into	NULL
the	NULL
Cu-in-ducible	NULL
pRmHa-3	NULL
Drosophila	NULL
expression	NULL
vector	NULL
.	NULL

For	NULL
class	NULL
II	NULL
production	NULL
,	NULL
DRa	NULL
and	NULL
DRB	NULL
expression	NULL
vectors	NULL
were	NULL
cotransfected	NULL
into	NULL
Schneider	NULL
S-2	NULL
cells	NULL
.	NULL

Soluble	NULL
class	NULL
II	NULL
molecules	NULL
produced	NULL
after	NULL
addition	NULL
of	NULL
CuSQ	NULL
,	NULL
were	NULL
purified	NULL
by	NULL
affinity	NULL
chromatography	NULL
,	NULL
concentrated	NULL
,	NULL
and	NULL
subsequently	NULL
biotinylated	NULL
with	NULL
the	NULL
Bir	NULL
A	NULL
enzyme	NULL
(	NULL
Avidity	NULL
,	NULL
Denver	NULL
,	NULL
CO	NULL
;	NULL
Ref	NULL
.	NULL

24	NULL
)	NULL
.	NULL

For	NULL
generation	NULL
of	NULL
tetramer	NULL
pools	NULL
,	NULL
a	NULL
panel	NULL
of	NULL
60	NULL
overlapping	NULL
VP16	NULL
peptides	NULL
,	NULL
p3	NULL
to	NULL
p62	NULL
,	NULL
were	NULL
used	NULL
.	NULL

These	NULL
peptides	NULL
,	NULL
each	NULL
20	NULL
aa	NULL
in	NULL
length	NULL
,	NULL
corresponded	NULL
to	NULL
the	NULL
entire	NULL
VP16	NULL
protein	NULL
with	NULL
a	NULL
12-aa	NULL
overlap	NULL
between	NULL
adjacent	NULL
peptides	NULL
.	NULL

Peptides	NULL
were	NULL
synthesized	NULL
on	NULL
polyethylene	NULL
pins	NULL
with	NULL
9-fluore-nylmethoxycarbony	NULL
]	NULL
chemistry	NULL
by	NULL
Chiron	NULL
Technologies	NULL
(	NULL
Clayton	NULL
,	NULL
Austra-lia	NULL
)	NULL
.	NULL

Individual	NULL
peptides	NULL
were	NULL
weighed	NULL
out	NULL
and	NULL
dissolved	NULL
in	NULL
DMSO	NULL
to	NULL
achieve	NULL
the	NULL
appropriate	NULL
peptide	NULL
concentration	NULL
.	NULL

The	NULL
peptides	NULL
were	NULL
divided	NULL
into	NULL
12	NULL
pools	NULL
,	NULL
each	NULL
containing	NULL
5	NULL
different	NULL
overlapping	NULL
peptides	NULL
.	NULL

Five	NULL
peptides	NULL
per	NULL
pool	NULL
was	NULL
found	NULL
to	NULL
preserve	NULL
sensitivity	NULL
in	NULL
identifying	NULL
individual	NULL
peptide	NULL
epitopes	NULL
.	NULL

A	NULL
similar	NULL
range	NULL
of	NULL
peptides	NULL
per	NULL
pool	NULL
has	NULL
been	NULL
used	NULL
in	NULL
earlier	NULL
epitope	NULL
mapping	NULL
studies	NULL
(	NULL
25	NULL
,	NULL
26	NULL
)	NULL
.	NULL

The	NULL
biotinylated	NULL
class	NULL
II	NULL
molecules	NULL
DRO401	NULL
and	NULL
DRO404	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
1	NULL
mg/ml	NULL
were	NULL
each	NULL
loaded	NULL
with	NULL
the	NULL
12	NULL
different	NULL
peptide	NULL
pools	NULL
by	NULL
incubation	NULL
for	NULL
48	NULL
h	NULL
at	NULL
37°C	NULL
with	NULL
25-fold	NULL
molar	NULL
excess	NULL
of	NULL
peptides	NULL
(	NULL
total	NULL
)	NULL
in	NULL
100	NULL
mM	NULL
sodium	NULL
phosphate	NULL
,	NULL
pH	NULL
6.0	NULL
,	NULL
and	NULL
0.2	NULL
%	NULL
n-octyl-p-glucopyranoside	NULL
.	NULL

Tetramers	NULL
were	NULL
formed	NULL
by	NULL
incubating	NULL
class	NULL
II	NULL
molecules	NULL
with	NULL
PE-labeled	NULL
streptavidin	NULL
(	NULL
BioSource	NULL
Inter-national	NULL
,	NULL
Camarillo	NULL
,	NULL
CA	NULL
)	NULL
for	NULL
6	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
at	NULL
a	NULL
molar	NULL
ratio	NULL
of	NULL
8	NULL
to	NULL
1	NULL
.	NULL

For	NULL
single	NULL
peptide	NULL
tetramers	NULL
,	NULL
the	NULL
peptide	NULL
was	NULL
loaded	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
5-fold	NULL
molar	NULL
excess	NULL
over	NULL
the	NULL
class	NULL
II	NULL
concentration	NULL
.	NULL

Staining	NULL
and	NULL
isolation	NULL
of	NULL
VP-16-specific	NULL
T	NULL
cells	NULL
PBMC	NULL
from	NULL
a	NULL
DRB1*0401	NULL
,	NULL
DRB1*0404	NULL
HSV-2-positive	NULL
individual	NULL
were	NULL
stimulated	NULL
with	NULL
VP16	NULL
protein	NULL
at	NULL
2	NULL
ug/ml	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
Chiron	NULL
Corporation	NULL
)	NULL
.	NULL

IL-2	NULL
was	NULL
added	NULL
(	NULL
10	NULL
U/ml	NULL
final	NULL
concentration	NULL
)	NULL
every	NULL
other	NULL
day	NULL
starting	NULL
on	NULL
day	NULL
5	NULL
.	NULL

T	NULL
cells	NULL
were	NULL
stained	NULL
with	NULL
tetramer	NULL
pools	NULL
on	NULL
day	NULL
11	NULL
or	NULL
12	NULL
.	NULL

For	NULL
each	NULL
pool	NULL
,	NULL
2	NULL
X	NULL
10°	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
0.5	NULL
pg	NULL
of	NULL
PE-labeled	NULL
tetramer	NULL
in	NULL
50	NULL
ul	NULL
of	NULL
culture	NULL
medium	NULL
(	NULL
10	NULL
ug/ml	NULL
!	NULL
)	NULL

at	NULL
37°C	NULL
for	NULL
1	NULL
to	NULL
2	NULL
h	NULL
,	NULL
and	NULL
then	NULL
stained	NULL
with	NULL
anti-CD4-FITC	NULL
(	NULL
BD	NULL
PharMingen	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
for	NULL
15	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Near	NULL
maximal	NULL
staining	NULL
of	NULL
T	NULL
cell	NULL
clones	NULL
was	NULL
observed	NULL
with	NULL
0.05	NULL
ug	NULL
of	NULL
tetramer	NULL
reagent	NULL
,	NULL
indicating	NULL
that	NULL
10	NULL
pg/ml	NULL
provides	NULL
an	NULL
excess	NULL
of	NULL
MHC	NULL
molecules	NULL
for	NULL
the	NULL
staining	NULL
reaction	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
and	NULL
analyzed	NULL
with	NULL
a	NULL
Becton	NULL
Dickinson	NULL
FACSCalibur	NULL
flow	NULL
cytometer	NULL
(	NULL
Becton	NULL
Dickinson	NULL
,	NULL
San	NULL
Jose	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Tetramers	NULL
loaded	NULL
with	NULL
the	NULL
corresponding	NULL
single	NULL
peptides	NULL
were	NULL
generated	NULL
for	NULL
those	NULL
pools	NULL
that	NULL
gave	NULL
positive	NULL
staining	NULL
,	NULL
and	NULL
analysis	NULL
was	NULL
done	NULL
on	NULL
day	NULL
14	NULL
or	NULL
15	NULL
.	NULL

Levels	NULL
of	NULL
background	NULL
staining	NULL
,	NULL
generally	NULL
around	NULL
0.1	NULL
%	NULL
,	NULL
were	NULL
determined	NULL
by	NULL
using	NULL
tetramers	NULL
loaded	NULL
with	NULL
an	NULL
irrelevant	NULL
peptide	NULL
,	NULL
HAsy	NULL
;	NULL
319	NULL
(	NULL
influenza	NULL
A	NULL
hemagglutinin	NULL
protein	NULL
,	NULL
residues	NULL
307-319	NULL
)	NULL
.	NULL

Cells	NULL
that	NULL
were	NULL
positive	NULL
for	NULL
a	NULL
particular	NULL
tetramer	NULL
were	NULL
single-cell	NULL
sorted	NULL
into	NULL
96-well	NULL
U-bottom	NULL
plates	NULL
by	NULL
using	NULL
a	NULL
Becton	NULL
Dickinson	NULL
FACSVantage	NULL
(	NULL
San	NULL
Jose	NULL
,	NULL
CA	NULL
)	NULL
on	NULL
the	NULL
same	NULL
or	NULL
following	NULL
day	NULL
.	NULL

Sorted	NULL
cells	NULL
were	NULL
expanded	NULL
with	NULL
1.5	NULL
X	NULL
10°	NULL
unmatched	NULL
,	NULL
irradiated	NULL
(	NULL
5000	NULL
rad	NULL
)	NULL
PBMC	NULL
per	NULL
well	NULL
as	NULL
feeders	NULL
with	NULL
2.5	NULL
ug/ml	NULL
PHA	NULL
and	NULL
10	NULL
U/ml	NULL
IL-2	NULL
added	NULL
24	NULL
h	NULL
later	NULL
.	NULL

Specificity	NULL
of	NULL
cloned	NULL
T	NULL
cells	NULL
was	NULL
confirmed	NULL
by	NULL
staining	NULL
with	NULL
tetramers	NULL
(	NULL
loaded	NULL
with	NULL
cognate	NULL
peptide	NULL
or	NULL
control	NULL
peptide	NULL
,	NULL
HAsp	NULL
;	NULL
31,4	NULL
)	NULL
and	NULL
T	NULL
cell	NULL
proliferation	NULL
assays	NULL
with	NULL
10	NULL
ug/ml	NULL
of	NULL
specific	NULL
peptide	NULL
and	NULL
DR-transfected	NULL
bare	NULL
lymphocyte	NULL
syndrome	NULL
(	NULL
BLS	NULL
)	NULL
line	NULL
BLS-DRA1*0O10L1/DRB1*0401	NULL
(	NULL
BLS-DRO401	NULL
)	NULL
or	NULL
BLS-DRA1*0101/DRB1*0404	NULL
(	NULL
BLS-DRO404	NULL
)	NULL
as	NULL
APCs	NULL
(	NULL
18	NULL
,	NULL
27	NULL
)	NULL
.	NULL

Competition	NULL
binding	NULL
assays	NULL
of	NULL
identified	NULL
peptides	NULL
were	NULL
performed	NULL
with	NULL
purified	NULL
DRO401	NULL
and	NULL
DRO404	NULL
protein	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
28	NULL
)	NULL
.	NULL

Measurement	NULL
of	NULL
cytokine	NULL
secretion	NULL
In	NULL
experiments	NULL
that	NULL
used	NULL
IFN-y	NULL
secretion	NULL
as	NULL
an	NULL
indicator	NULL
of	NULL
T	NULL
cell	NULL
reactiv-ity	NULL
,	NULL
PBMC	NULL
were	NULL
stimulated	NULL
with	NULL
VP16	NULL
protein	NULL
as	NULL
described	NULL
above	NULL
and	NULL
assayed	NULL
on	NULL
day	NULL
11	NULL
or	NULL
12	NULL
.	NULL

PBMC	NULL
(	NULL
1	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
incubated	NULL
together	NULL
with	NULL
an	NULL
equal	NULL
number	NULL
of	NULL
BLS-DRO401	NULL
or	NULL
BLS-DRO404	NULL
APCs	NULL
that	NULL
had	NULL
been	NULL
pulsed	NULL
with	NULL
50	NULL
ug/ml	NULL
of	NULL
each	NULL
peptide	NULL
pool	NULL
.	NULL

After	NULL
3	NULL
h	NULL
of	NULL
incubation	NULL
,	NULL
IFN-y	NULL
secretion	NULL
was	NULL
determined	NULL
by	NULL
use	NULL
of	NULL
a	NULL
cytokine	NULL
secretion	NULL
capture	NULL
assay	NULL
following	NULL
the	NULL
protocol	NULL
supplied	NULL
by	NULL
the	NULL
manufacturer	NULL
(	NULL
Miltenyi	NULL
Biotec	NULL
,	NULL
Auburn	NULL
,	NULL
CA	NULL
;	NULL
Ref	NULL
.	NULL

29	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
cells	NULL
were	NULL
washed	NULL
once	NULL
in	NULL
PBS	NULL
and	NULL
incubated	NULL
in	NULL
100	NULL
pl	NULL
of	NULL
medium	NULL
on	NULL
ice	NULL
for	NULL
5	NULL
min	NULL
with	NULL
an	NULL
Ab-Ab	NULL
conjugate	NULL
directed	NULL
against	NULL
both	NULL
CD45	NULL
and	NULL
IFN-y	NULL
.	NULL

Prewarmed	NULL
medium	NULL
was	NULL
added	NULL
to	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
2	NULL
ml	NULL
,	NULL
and	NULL
cells	NULL
were	NULL
incubated	NULL
at	NULL
37°C	NULL
for	NULL
45	NULL
min	NULL
under	NULL
gentle	NULL
rotation	NULL
to	NULL
allow	NULL
cell	NULL
surface	NULL
capture	NULL
of	NULL
secreted	NULL
IFN-y	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
once	NULL
in	NULL
PBS	NULL
and	NULL
then	NULL
stained	NULL
for	NULL
15	NULL
min	NULL
on	NULL
ice	NULL
with	NULL
a	NULL
second	NULL
PE-conjugated	NULL
Ab	NULL
directed	NULL
against	NULL
IFN-y	NULL
as	NULL
well	NULL
as	NULL
a	NULL
FITC-conjugated	NULL
Ab	NULL
directed	NULL
against	NULL
CD4	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
once	NULL
in	NULL
PBS	NULL
and	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
as	NULL
described	NULL
TETRAMER-GUIDED	NULL
EPITOPE	NULL
MAPPING	NULL
(	NULL
TGEM	NULL
)	NULL
above	NULL
.	NULL

For	NULL
pools	NULL
that	NULL
showed	NULL
significant	NULL
IFN-y	NULL
staining	NULL
,	NULL
reactivities	NULL
of	NULL
individual	NULL
peptides	NULL
were	NULL
assayed	NULL
by	NULL
the	NULL
same	NULL
approach	NULL
.	NULL

Results	NULL
Epitope	NULL
mapping	NULL
with	NULL
class	NULL
II	NULL
tetramer	NULL
pools	NULL
To	NULL
determine	NULL
the	NULL
class	NULL
II-restricted	NULL
epitopes	NULL
of	NULL
the	NULL
HSV-2	NULL
VP16	NULL
protein	NULL
,	NULL
peptides	NULL
of	NULL
20	NULL
aa	NULL
in	NULL
length	NULL
spanning	NULL
the	NULL
entire	NULL
sequence	NULL
of	NULL
the	NULL
VP16	NULL
protein	NULL
,	NULL
with	NULL
a	NULL
12-aa	NULL
overlap	NULL
between	NULL
consecutive	NULL
peptides	NULL
,	NULL
were	NULL
used	NULL
to	NULL
generate	NULL
two	NULL
tetramer	NULL
panels	NULL
,	NULL
one	NULL
for	NULL
the	NULL
DRO401	NULL
molecules	NULL
and	NULL
the	NULL
other	NULL
for	NULL
the	NULL
DRO404	NULL
molecules	NULL
.	NULL

Each	NULL
panel	NULL
included	NULL
12	NULL
different	NULL
tetramer	NULL
pools	NULL
,	NULL
designated	NULL
as	NULL
pool	NULL
1	NULL
to	NULL
pool	NULL
12	NULL
.	NULL

Each	NULL
pool	NULL
contained	NULL
the	NULL
soluble	NULL
class	NULL
II	NULL
molecules	NULL
together	NULL
with	NULL
five	NULL
different	NULL
peptides	NULL
of	NULL
the	NULL
VP16	NULL
protein	NULL
.	NULL

With	NULL
these	NULL
two	NULL
tetramer	NULL
panels	NULL
,	NULL
we	NULL
analyzed	NULL
PBMC	NULL
from	NULL
a	NULL
DRB1*0401	NULL
,	NULL
DRB1*0404	NULL
HSV-2-positive	NULL
individual	NULL
.	NULL

Cells	NULL
were	NULL
stimulated	NULL
with	NULL
2	NULL
ug/ml	NULL
of	NULL
VP16	NULL
protein	NULL
and	NULL
11	NULL
or	NULL
12	NULL
days	NULL
following	NULL
stimulation	NULL
were	NULL
stained	NULL
with	NULL
each	NULL
tetramer	NULL
panel	NULL
.	NULL

Four	NULL
pools	NULL
,	NULL
2	NULL
,	NULL
5	NULL
,	NULL
6	NULL
and	NULL
12	NULL
,	NULL
gave	NULL
significant	NULL
staining	NULL
above	NULL
background	NULL
with	NULL
the	NULL
DRO401	NULL
tetramer	NULL
panel	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

Staining	NULL
with	NULL
the	NULL
DRO404	NULL
tetramer	NULL
panel	NULL
identified	NULL
two	NULL
pools	NULL
,	NULL
6	NULL
and	NULL
12	NULL
,	NULL
as	NULL
having	NULL
significant	NULL
staining	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

We	NULL
then	NULL
generated	NULL
tetramers	NULL
loaded	NULL
with	NULL
the	NULL
individual	NULL
peptides	NULL
of	NULL
the	NULL
positive	NULL
pools	NULL
and	NULL
used	NULL
these	NULL
to	NULL
determine	NULL
which	NULL
peptide	NULL
epitopes	NULL
in	NULL
the	NULL
pool	NULL
were	NULL
recognized	NULL
by	NULL
responding	NULL
T	NULL
cells	NULL
.	NULL

For	NULL
DROQ401/pool	NULL
2	NULL
,	NULL
peptides	NULL
p9	NULL
,	NULL
p10	NULL
,	NULL
and	NULL
p12	NULL
DRO401/Pooled	NULL
peptide	NULL
tetramer	NULL
60	NULL
-	NULL
3	NULL
03	NULL
%	NULL
01	NULL
%	NULL
4	NULL
-	NULL
02	NULL
%	NULL
'	NULL
o	NULL
mms	NULL
20.6	NULL
%	NULL
79.0	NULL
%	NULL
-	NULL
21.0	NULL
%	NULL
78.7	NULL
%	NULL
o0	NULL
%	NULL
_	NULL
T	NULL
03	NULL
%	NULL
0.0	NULL
%	NULL
8	NULL
-	NULL
03	NULL
%	NULL
DRO404/Pooled	NULL
peptide	NULL
tetramer	NULL
tor	NULL
21.2	NULL
%	NULL
CD4	NULL
FIGURE	NULL
1	NULL
.	NULL

Identification	NULL
of	NULL
VP16	NULL
epitopes	NULL
by	NULL
using	NULL
pooled	NULL
peptide	NULL
tetramers	NULL
.	NULL

PBMC	NULL
stimulated	NULL
with	NULL
2	NULL
pg/ml	NULL
VP16	NULL
protein	NULL
were	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
on	NULL
day	NULL
11	NULL
or	NULL
12	NULL
.	NULL

Cells	NULL
were	NULL
stained	NULL
with	NULL
either	NULL
(	NULL
4	NULL
)	NULL
DRO401	NULL
or	NULL
(	NULL
B	NULL
)	NULL
DRO404	NULL
tetramers	NULL
loaded	NULL
with	NULL
peptides	NULL
from	NULL
each	NULL
of	NULL
12	NULL
peptide	NULL
pools	NULL
that	NULL
cover	NULL
the	NULL
VP16	NULL
protein	NULL
sequence	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Each	NULL
panel	NULL
shows	NULL
analysis	NULL
of	NULL
at	NULL
least	NULL
3	NULL
X	NULL
10°	NULL
cells	NULL
,	NULL
and	NULL
percentages	NULL
represent	NULL
the	NULL
percent	NULL
of	NULL
total	NULL
cells	NULL
in	NULL
each	NULL
quadrant	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
gave	NULL
positive	NULL
staining	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
;	NULL
for	NULL
DRO401/pool	NULL
6	NULL
,	NULL
peptide	NULL
p32	NULL
gave	NULL
positive	NULL
staining	NULL
;	NULL
and	NULL
for	NULL
DRO401/pool	NULL
12	NULL
,	NULL
peptides	NULL
p61	NULL
and	NULL
p62	NULL
gave	NULL
positive	NULL
staining	NULL
.	NULL

We	NULL
were	NULL
unable	NULL
to	NULL
identify	NULL
any	NULL
individual	NULL
peptides	NULL
for	NULL
pool	NULL
5	NULL
despite	NULL
repeated	NULL
attempts	NULL
.	NULL

We	NULL
speculate	NULL
that	NULL
this	NULL
may	NULL
reflect	NULL
T	NULL
cells	NULL
of	NULL
low	NULL
avidity	NULL
,	NULL
which	NULL
are	NULL
difficult	NULL
to	NULL
consistently	NULL
stain	NULL
using	NULL
tetramers	NULL
.	NULL

For	NULL
DRO404/pool	NULL
6	NULL
,	NULL
peptides	NULL
p31	NULL
and	NULL
p32	NULL
gave	NULL
positive	NULL
staining	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
;	NULL
and	NULL
for	NULL
DRO404/pool	NULL
12	NULL
,	NULL
peptide	NULL
p58	NULL
showed	NULL
positive	NULL
staining	NULL
.	NULL

To	NULL
assess	NULL
the	NULL
efficiency	NULL
of	NULL
pooled-peptide	NULL
tetramers	NULL
in	NULL
identifying	NULL
T	NULL
cell	NULL
epitopes	NULL
,	NULL
we	NULL
compared	NULL
our	NULL
approach	NULL
with	NULL
that	NULL
of	NULL
Kern	NULL
and	NULL
colleagues	NULL
(	NULL
25	NULL
)	NULL
who	NULL
used	NULL
IFN-y	NULL
production	NULL
as	NULL
an	NULL
indicator	NULL
for	NULL
epitope-specific	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
stimulated	NULL
with	NULL
2	NULL
ug/ml	NULL
of	NULL
VP16	NULL
protein	NULL
and	NULL
11	NULL
or	NULL
12	NULL
days	NULL
following	NULL
stimulation	NULL
were	NULL
restimulated	NULL
for	NULL
3	NULL
h	NULL
with	NULL
BLS-DRO401	NULL
or	NULL
BLS-DRO404	NULL
cell	NULL
lines	NULL
pulsed	NULL
with	NULL
50	NULL
g/ml	NULL
of	NULL
each	NULL
peptide	NULL
pool	NULL
.	NULL

For	NULL
PBMC	NULL
stimulated	NULL
with	NULL
the	NULL
BLS-DRO401	NULL
cell	NULL
line	NULL
,	NULL
pools	NULL
2	NULL
,	NULL
5	NULL
,	NULL
and	NULL
12	NULL
were	NULL
positive	NULL
for	NULL
IFN-y	NULL
secretion	NULL
as	NULL
measured	NULL
by	NULL
flow	NULL
cytometry	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

As	NULL
seen	NULL
in	NULL
Fig	NULL
.	NULL

14	NULL
,	NULL
both	NULL
pools	NULL
2	NULL
and	NULL
12	NULL
were	NULL
positive	NULL
in	NULL
the	NULL
DRO401	NULL
tetramer	NULL
analysis	NULL
.	NULL

Pool	NULL
5	NULL
was	NULL
positive	NULL
in	NULL
the	NULL
tetramer	NULL
screen	NULL
;	NULL
however	NULL
,	NULL
as	NULL
noted	NULL
,	NULL
we	NULL
were	NULL
unable	NULL
to	NULL
see	NULL
tetramer	NULL
staining	NULL
with	NULL
the	NULL
individual	NULL
peptides	NULL
of	NULL
pool	NULL
5	NULL
.	NULL

Interestingly	NULL
,	NULL
pool	NULL
6	NULL
,	NULL
which	NULL
was	NULL
positive	NULL
in	NULL
the	NULL
tetramer	NULL
screen	NULL
,	NULL
did	NULL
not	NULL
show	NULL
appreciable	NULL
IFN-y	NULL
production	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
although	NULL
the	NULL
two	NULL
methods	NULL
generally	NULL
coincide	NULL
,	NULL
differences	NULL
in	NULL
what	NULL
each	NULL
approach	NULL
measures	NULL
,	NULL
TCR/MHC	NULL
avidity	NULL
with	NULL
tetramers	NULL
and	NULL
specific	NULL
effector	NULL
function	NULL
with	NULL
IFN-y	NULL
production	NULL
,	NULL
allows	NULL
each	NULL
method	NULL
to	NULL
identify	NULL
occasional	NULL
cells	NULL
that	NULL
would	NULL
be	NULL
undetectable	NULL
by	NULL
the	NULL
alternate	NULL
approach	NULL
.	NULL

Characterization	NULL
of	NULL
tetramer-positive	NULL
T	NULL
cell	NULL
clones	NULL
T	NULL
cells	NULL
that	NULL
were	NULL
specific	NULL
for	NULL
peptides	NULL
p10	NULL
and	NULL
p61	NULL
for	NULL
DRO401	NULL
and	NULL
peptide	NULL
p58	NULL
for	NULL
DRO404	NULL
were	NULL
isolated	NULL
and	NULL
tested	NULL
for	NULL
specificity	NULL
.	NULL

A	NULL
6667	NULL
Tetramer-positive	NULL
T	NULL
cells	NULL
were	NULL
single-cell	NULL
sorted	NULL
and	NULL
expanded	NULL
,	NULL
and	NULL
>	NULL
20	NULL
clones	NULL
specific	NULL
for	NULL
each	NULL
DR/peptide	NULL
complex	NULL
were	NULL
iden-tified	NULL
.	NULL

All	NULL
of	NULL
the	NULL
clones	NULL
obtained	NULL
demonstrated	NULL
Ag	NULL
specificity	NULL
as	NULL
shown	NULL
by	NULL
proliferation	NULL
assays	NULL
and	NULL
tetramer	NULL
staining	NULL
.	NULL

Tetramer	NULL
staining	NULL
and	NULL
proliferation	NULL
data	NULL
are	NULL
shown	NULL
for	NULL
three	NULL
different	NULL
clones	NULL
for	NULL
each	NULL
specificity	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Although	NULL
strong	NULL
staining	NULL
and	NULL
Ag-specific	NULL
proliferation	NULL
were	NULL
observed	NULL
for	NULL
most	NULL
clones	NULL
,	NULL
there	NULL
existed	NULL
variations	NULL
in	NULL
staining	NULL
intensity	NULL
and	NULL
degree	NULL
of	NULL
proliferation	NULL
for	NULL
a	NULL
number	NULL
of	NULL
clones	NULL
.	NULL

Some	NULL
of	NULL
these	NULL
atypical	NULL
patterns	NULL
are	NULL
illustrated	NULL
in	NULL
Fig	NULL
.	NULL

4C	NULL
with	NULL
DRO4O01-restricted	NULL
clones	NULL
specific	NULL
for	NULL
p10	NULL
.	NULL

Both	NULL
clones	NULL
p10-1	NULL
and	NULL
p10-2	NULL
consistently	NULL
showed	NULL
a	NULL
broader	NULL
range	NULL
of	NULL
staining	NULL
intensity	NULL
compared	NULL
with	NULL
the	NULL
majority	NULL
of	NULL
clones	NULL
,	NULL
which	NULL
showed	NULL
more	NULL
focal	NULL
staining	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
clone	NULL
p10-3	NULL
consistently	NULL
showed	NULL
poor	NULL
tetramer	NULL
staining	NULL
despite	NULL
vigorous	NULL
proliferation	NULL
to	NULL
specific	NULL
peptide	NULL
.	NULL

We	NULL
speculate	NULL
that	NULL
these	NULL
different	NULL
staining	NULL
patterns	NULL
reflect	NULL
different	NULL
avidities	NULL
of	NULL
the	NULL
TCR	NULL
for	NULL
the	NULL
MHC/peptide	NULL
complex	NULL
in	NULL
the	NULL
different	NULL
clones	NULL
.	NULL

These	NULL
atypical	NULL
staining	NULL
patterns	NULL
were	NULL
not	NULL
unique	NULL
to	NULL
clones	NULL
restricted	NULL
to	NULL
p10	NULL
;	NULL
a	NULL
few	NULL
clones	NULL
specific	NULL
for	NULL
p58	NULL
and	NULL
p61	NULL
also	NULL
showed	NULL
weak	NULL
staining	NULL
,	NULL
whereas	NULL
clones	NULL
specific	NULL
for	NULL
p10	NULL
with	NULL
strong	NULL
staining	NULL
were	NULL
also	NULL
observed	NULL
.	NULL

To	NULL
more	NULL
precisely	NULL
define	NULL
the	NULL
epitopes	NULL
recognized	NULL
by	NULL
the	NULL
T	NULL
cell	NULL
clones	NULL
,	NULL
we	NULL
evaluated	NULL
probable	NULL
DRO401	NULL
and	NULL
DRO404	NULL
peptide	NULL
binding	NULL
motifs	NULL
by	NULL
using	NULL
truncation	NULL
analyses	NULL
.	NULL

A	NULL
number	NULL
of	NULL
studies	NULL
have	NULL
extensively	NULL
characterized	NULL
the	NULL
peptide-binding	NULL
motifs	NULL
for	NULL
DR4	NULL
(	NULL
30-32	NULL
)	NULL
.	NULL

Examination	NULL
of	NULL
peptide	NULL
p10	NULL
(	NULL
VP164	NULL
,	NULL
,	NULL
,	NULL
)	NULL
revealed	NULL
that	NULL
the	NULL
12-mer	NULL
peptide	NULL
VP165	NULL
,	NULL
;	NULL
,	NULL
possesses	NULL
good	NULL
DRO401	NULL
binding	NULL
mo-tifs	NULL
.	NULL

Experiments	NULL
with	NULL
the	NULL
VP16	NULL
;	NULL
,	NULL
_	NULL
,	NULL
,	NULL
peptide	NULL
demonstrated	NULL
that	NULL
the	NULL
peptide	NULL
could	NULL
indeed	NULL
stimulate	NULL
the	NULL
DRO4O01-restricted	NULL
T	NULL
cell	NULL
clones	NULL
specific	NULL
for	NULL
the	NULL
p10	NULL
epitope	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
positive	NULL
staining	NULL
observed	NULL
in	NULL
Fig	NULL
.	NULL

24	NULL
with	NULL
the	NULL
DRO401/p9	NULL
tetramers	NULL
was	NULL
likely	NULL
attributable	NULL
to	NULL
the	NULL
overlapping	NULL
of	NULL
0.1	NULL
%	NULL
0.0	NULL
%	NULL
10s	NULL
_	NULL
POOL	NULL
2	NULL
0.5	NULL
%	NULL
-	NULL
014	NULL
%	NULL
16	NULL
%	NULL
-	NULL
0.0	NULL
%	NULL
02	NULL
%	NULL
-_	NULL
0.5	NULL
%	NULL
1.8	NULL
%	NULL
p9	NULL
a	NULL
p10	NULL
,	NULL
-	NULL
p11	NULL
p12	NULL
a	NULL
18.8	NULL
%	NULL
2	NULL
%	NULL
pog	NULL
of	NULL
go	NULL
?	NULL

go	NULL
:	NULL
or	NULL
oo	NULL
100	NULL
gor	NULL
gor	NULL
go	NULL
>	NULL
.	NULL

go	NULL
100	NULL
gor	NULL
gor	NULL
go	NULL
>	NULL
oe	NULL
dor	NULL
fo	NULL
?	NULL

``	NULL
fo	NULL
'	NULL
of	NULL
18.2	NULL
%	NULL
79.5	NULL
%	NULL
o	NULL
o	NULL
o	NULL
o	NULL
90/0	NULL
p31	NULL
0.2	NULL
%	NULL
EMA	NULL
;	NULL
p32	NULL
1.1	NULL
%	NULL
o	NULL
``	NULL
``	NULL
To	NULL
``	NULL
``	NULL
Toi	NULL
o-81.0	NULL
%	NULL
.	NULL

19.8	NULL
%	NULL
79.7	NULL
%	NULL
0.1	NULL
%	NULL
1	NULL
%	NULL
p29	NULL
0.2	NULL
%	NULL
PooLé6	NULL
&	NULL
FIGURE	NULL
2	NULL
.	NULL

Defining	NULL
individual	NULL
VP16	NULL
epitopes	NULL
from	NULL
peptide	NULL
pools	NULL
.	NULL

The	NULL
individual	NULL
peptide	NULL
constituents	NULL
from	NULL
those	NULL
pools	NULL
that	NULL
gave	NULL
positive	NULL
staining	NULL
DRO401	NULL
single	NULL
peptide	NULL
tetramer	NULL
el	NULL
gor	NULL
gor	NULL
gor	NULL
get	NULL
©	NULL
100	NULL
.	NULL

gos	NULL
.	NULL

gor	NULL
.	NULL

go	NULL
x	NULL
.	NULL

``	NULL
Io	NULL
go	NULL
fo	NULL
``	NULL
an	NULL
)	NULL
05	NULL
``	NULL
To	NULL
254	NULL
%	NULL
74.3	NULL
%	NULL
25.4	NULL
%	NULL
ELM/a	NULL
5	NULL
%	NULL
p62	NULL
5.1	NULL
%	NULL
R	NULL
oh	NULL
``	NULL
Tol	NULL
Ho	NULL
:	NULL
0	NULL
``	NULL
To	NULL
:	NULL
74.6	NULL
%	NULL
28.8	NULL
%	NULL
70.9	NULL
%	NULL
73.4	NULL
%	NULL
0.4	NULL
%	NULL
9.0	NULL
%	NULL
p59	NULL
0.2	NULL
%	NULL
were	NULL
singularly	NULL
loaded	NULL
into	NULL
tetramers	NULL
of	NULL
the	NULL
same	NULL
DR	NULL
type	NULL
.	NULL

These	NULL
single	NULL
peptide	NULL
tetramers	NULL
were	NULL
then	NULL
10	NULL
_	NULL
jot	NULL
©	NULL
used	NULL
to	NULL
stain	NULL
the	NULL
same	NULL
PBMC	NULL
previously	NULL
stained	NULL
Poot	NULL
12	NULL
j	NULL
with	NULL
pooled	NULL
peptide	NULL
tetramers	NULL
.	NULL

Each	NULL
row	NULL
shows	NULL
the	NULL
tetramer	NULL
staining	NULL
for	NULL
the	NULL
constituent	NULL
peptides	NULL
of	NULL
(	NULL
4	NULL
)	NULL
120	NULL
%	NULL
pool	NULL
2	NULL
,	NULL
pool	NULL
6	NULL
,	NULL
and	NULL
pool	NULL
12	NULL
for	NULL
DRO401	NULL
,	NULL
and	NULL
(	NULL
B	NULL
)	NULL
pool	NULL
6	NULL
and	NULL
pool	NULL
12	NULL
for	NULL
DRO404	NULL
.	NULL

Each	NULL
panel	NULL
shows	NULL
anal	NULL
100	NULL
gon	NULL
go	NULL
>	NULL
o	NULL
D	NULL
?	NULL

0°	NULL
of	NULL
17.6	NULL
%	NULL
76.8	NULL
%	NULL
os	NULL
76.7	NULL
%	NULL
0.3	NULL
%	NULL
e	NULL
0.6	NULL
%	NULL
?	NULL

2	NULL
%	NULL
p29	NULL
0.4	NULL
%	NULL
14	NULL
%	NULL
a	NULL
&	NULL
C	NULL
to	NULL
hes	NULL
a	NULL
a	NULL
ysis	NULL
of	NULL
at	NULL
least	NULL
3	NULL
X	NULL
10°	NULL
cells	NULL
,	NULL
and	NULL
percentages	NULL
represent	NULL
the	NULL
percent	NULL
of	NULL
total	NULL
cells	NULL
in	NULL
each	NULL
quadrant	NULL
.	NULL

p32	NULL
o	NULL
o	NULL
19.	NULL
jov	NULL
9	NULL
o	NULL
Walk	NULL
t	NULL
POOL	NULL
6	NULL
&	NULL
10	NULL
:	NULL
Noo	NULL
©	NULL
s	NULL
io	NULL
€	NULL
a	NULL
~	NULL
3	NULL
5	NULL
6	NULL
no	NULL
bo	NULL
&	NULL
a	NULL
3	NULL
a	NULL
i	NULL
den	NULL
0	NULL
o	NULL
DRO404	NULL
single	NULL
peptide	NULL
tetramer	NULL
&	NULL
POOL	NULL
12	NULL
&	NULL
10°	NULL
.	NULL

jor	NULL
.	NULL

to	NULL
&	NULL
oY	NULL
or	NULL
oF	NULL
``	NULL
to	NULL
!	NULL
``	NULL

Tor	NULL
oy	NULL
do	NULL
o	NULL
fo	NULL
!	NULL

Tor	NULL
to	NULL
?	NULL

o*	NULL
17.9	NULL
%	NULL
82.0	NULL
%	NULL
7.0	NULL
%	NULL
82.9	NULL
%	NULL
16.6	NULL
%	NULL
83.0	NULL
%	NULL
»	NULL
CD4	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
6668	NULL
TETRAMER-GUIDED	NULL
EPITOPE	NULL
MAPPING	NULL
(	NULL
TGEM	NULL
)	NULL
A	NULL
0.0	NULL
%	NULL
4	NULL
0.1	NULL
%	NULL
0.1	NULL
%	NULL
2	NULL
1.5	NULL
%	NULL
0.1	NULL
%	NULL
3	NULL
0.1	NULL
%	NULL
0.1	NULL
%	NULL
4	NULL
0.2	NULL
%	NULL
4	NULL
#	NULL
s	NULL
&	NULL
o	NULL
&	NULL
o	NULL
>	NULL
o|	NULL
;	NULL
:	NULL
719	NULL
``	NULL
10	NULL
o	NULL
d	NULL
ro	NULL
``	NULL
19	NULL
Td	NULL
10	NULL
.	NULL

10	NULL
``	NULL
hos	NULL
”	NULL
9102	NULL
7100	NULL
0°	NULL
19	NULL
o	NULL
10	NULL
d	NULL
ree	NULL
26.2	NULL
%	NULL
73.6	NULL
%	NULL
27.2	NULL
%	NULL
71.2	NULL
%	NULL
27.1	NULL
%	NULL
72.2	NULL
%	NULL
29.9	NULL
%	NULL
69.8	NULL
%	NULL
0.1	NULL
%	NULL
5	NULL
1.8	NULL
%	NULL
0.0	NULL
%	NULL
6	NULL
0.4	NULL
%	NULL
0.1	NULL
%	NULL
7	NULL
0.3	NULL
%	NULL
0.0	NULL
%	NULL
8	NULL
0.1	NULL
%	NULL
FIGURE	NULL
3	NULL
.	NULL

Cytokine	NULL
production	NULL
after	NULL
pooled	NULL
pep-	NULL
h	NULL
£	NULL
=	NULL
£	NULL
tide	NULL
stimulation	NULL
.	NULL

PBMC	NULL
stimulated	NULL
with	NULL
2	NULL
ug/ml	NULL
VP16	NULL
>	NULL
.	NULL

#	NULL
&	NULL
8	NULL
*	NULL
protein	NULL
were	NULL
analyzed	NULL
on	NULL
day	NULL
11	NULL
or	NULL
12	NULL
.	NULL

For	NULL
each	NULL
peptide	NULL
Z	NULL
B	NULL
AL	NULL
®	NULL
©	NULL
R	NULL
B	NULL
pool	NULL
,	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
3	NULL
h	NULL
with	NULL
BLS-DRO401	NULL
LL	NULL
%	NULL
X	NULL
£	NULL
$	NULL
dicts	NULL
,	NULL
>	NULL
_	NULL
APCs	NULL
pulsed	NULL
with	NULL
50	NULL
ug/ml	NULL
of	NULL
total	NULL
peptide	NULL
.	NULL

IFN-y	NULL
se-	NULL
-	NULL
]	NULL
*e	NULL
|	NULL
byt	NULL
.	NULL

g	NULL
?	NULL
)	NULL

Q	NULL
.	NULL

15:1	NULL
?	NULL

ty	NULL
.	NULL
}	NULL

tm	NULL
cretion	NULL
was	NULL
measured	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Each	NULL
panel	NULL
hoo	NULL
``	NULL
io	NULL
io	NULL
hon	NULL
o	NULL
o	NULL
g	NULL
o	NULL
hen	NULL
Wud	NULL
R	NULL
io	NULL
hen	NULL
o	NULL
id	NULL
S	NULL
o	NULL
ho	NULL
shows	NULL
analysis	NULL
of	NULL
at	NULL
least	NULL
3	NULL
X	NULL
10°	NULL
cells	NULL
,	NULL
and	NULL
percentages	NULL
29.1	NULL
%	NULL
69.0	NULL
%	NULL
.	NULL

28.8	NULL
%	NULL
108	NULL
%	NULL
52.0	NULL
%	NULL
50.5	NULL
%	NULL
9.2	NULL
%	NULL
10.6	NULL
%	NULL
,	NULL
o	NULL
represent	NULL
the	NULL
percent	NULL
of	NULL
total	NULL
cells	NULL
in	NULL
each	NULL
quadrant	NULL
.	NULL

2:05	NULL
H	NULL
(	NULL
100A	NULL
)	NULL
10	NULL
98	NULL
%	NULL
200A	NULL
)	NULL
44	NULL
906	NULL
%	NULL
$	NULL
2	NULL
%	NULL
42	NULL
28	NULL
%	NULL
1—	NULL
,	NULL
—	NULL
tas	NULL
5	NULL
~	NULL
€	NULL
]	NULL
:	NULL
]	NULL
£	NULL
Rf	NULL
i	NULL
§	NULL
718	NULL
``	NULL
T	NULL
o	NULL
d	NULL
ho	NULL
19	NULL
id	NULL
10	NULL
ido	NULL
``	NULL
18	NULL
``	NULL
id	NULL
``	NULL
18	NULL
``	NULL
10	NULL
``	NULL
hos	NULL
kry	NULL
;	NULL
o	NULL
‘	NULL
[	NULL
107	NULL
10°	NULL
10°	NULL
31.3	NULL
%	NULL
68.5	NULL
%	NULL
35.5	NULL
%	NULL
63.9	NULL
%	NULL
32.0	NULL
%	NULL
67.3	NULL
%	NULL
32.6	NULL
%	NULL
64.3	NULL
%	NULL
>	NULL
CD4	NULL
peptide	NULL
p9	NULL
(	NULL
VP16	NULL
,	NULL
,	NULL
_	NULL
,	NULL
,	NULL
,	NULL
)	NULL
and	NULL
peptide	NULL
p10	NULL
(	NULL
VP16	NULL
,	NULL
,	NULL
_	NULL
,	NULL
,	NULL
)	NULL
,	NULL
as	NULL
both	NULL
peptides	NULL
contain	NULL
the	NULL
shorter	NULL
epitope	NULL
.	NULL

Similar	NULL
examination	NULL
of	NULL
peptide	NULL
p61	NULL
(	NULL
VP16,4	NULL
;	NULL
5	NULL
4	NULL
&	NULL
4	NULL
)	NULL
identified	NULL
a	NULL
13-mer	NULL
peptide	NULL
,	NULL
VP16	NULL
,	NULL
;	NULL
,	NULL
,	NULL
,	NULL
&	NULL
,	NULL
,	NULL
which	NULL
stimulated	NULL
DRO40	NULL
!	NULL

1	NULL
restricted	NULL
T	NULL
cell	NULL
clones	NULL
directed	NULL
against	NULL
the	NULL
p61	NULL
epitope	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
positive	NULL
staining	NULL
seen	NULL
with	NULL
the	NULL
DRO401/p62	NULL
tetramer	NULL
in	NULL
Fig	NULL
.	NULL

2A	NULL
was	NULL
likely	NULL
attributable	NULL
to	NULL
the	NULL
overlapping	NULL
of	NULL
peptides	NULL
p61	NULL
and	NULL
p62	NULL
.	NULL

These	NULL
results	NULL
also	NULL
demonstrate	NULL
that	NULL
tetramer	NULL
staining	NULL
with	NULL
overlapping	NULL
peptides	NULL
provides	NULL
an	NULL
alternative	NULL
approach	NULL
to	NULL
directly	NULL
mapping	NULL
minimal	NULL
epitopes	NULL
.	NULL

Truncation	NULL
studies	NULL
with	NULL
peptide	NULL
p58	NULL
refined	NULL
the	NULL
DRO404-restricted	NULL
epitope	NULL
to	NULL
the	NULL
132-mer	NULL
VP16	NULL
,	NULL
,	NULL
;	NULL
455	NULL
,	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
DRO401-restricted	NULL
and	NULL
the	NULL
DRO404-restricted	NULL
epitopes	NULL
as	NULL
characterized	NULL
in	NULL
the	NULL
truncation	NULL
studies	NULL
are	NULL
listed	NULL
in	NULL
Table	NULL
I.	NULL
Interestingly	NULL
,	NULL
the	NULL
DRO404-restricted	NULL
443-455	NULL
epitope	NULL
is	NULL
not	NULL
found	NULL
as	NULL
a	NULL
DRO401-restricted	NULL
epitope	NULL
,	NULL
nor	NULL
are	NULL
the	NULL
58-69	NULL
and	NULL
472-484	NULL
DRO401-restricted	NULL
epitopes	NULL
found	NULL
as	NULL
DRO404-restricted	NULL
epitopes	NULL
.	NULL

In	NULL
vitro	NULL
peptide	NULL
binding	NULL
was	NULL
analyzed	NULL
with	NULL
purified	NULL
DRO401	NULL
and	NULL
DRO404	NULL
molecules	NULL
.	NULL

Peptides	NULL
from	NULL
the	NULL
DRO401-restricted	NULL
epitopes	NULL
(	NULL
VP165	NULL
;	NULL
_4	NULL
,	NULL
and	NULL
bind	NULL
with	NULL
a	NULL
much	NULL
lower	NULL
affinity	NULL
to	NULL
DRO404	NULL
compared	NULL
with	NULL
the	NULL
DRO4O4	NULL
restricted	NULL
peptide	NULL
45s	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
affinity	NULL
of	NULL
the	NULL
epitope	NULL
for	NULL
DRO401	NULL
is	NULL
lower	NULL
when	NULL
compared	NULL
with	NULL
peptides	NULL
58-69	NULL
and	NULL
472-484	NULL
,	NULL
although	NULL
the	NULL
magnitude	NULL
of	NULL
this	NULL
difference	NULL
is	NULL
not	NULL
as	NULL
great	NULL
with	NULL
peptide	NULL
58-69	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

These	NULL
experimental	NULL
observations	NULL
are	NULL
in	NULL
agreement	NULL
with	NULL
previous	NULL
reports	NULL
that	NULL
the	NULL
limited	NULL
polymorphism	NULL
between	NULL
these	NULL
alleles	NULL
at	NULL
codons	NULL
86	NULL
and	NULL
71	NULL
of	NULL
the	NULL
DRB1	NULL
chain	NULL
may	NULL
dictate	NULL
unique	NULL
binding	NULL
patterns	NULL
,	NULL
although	NULL
factors	NULL
other	NULL
than	NULL
peptide	NULL
binding	NULL
also	NULL
are	NULL
likely	NULL
important	NULL
in	NULL
dictating	NULL
which	NULL
epitopes	NULL
become	NULL
immunodominant	NULL
for	NULL
each	NULL
allele	NULL
(	NULL
33	NULL
,	NULL
34	NULL
)	NULL
.	NULL

Discussion	NULL
The	NULL
tetramer-guided	NULL
epitope	NULL
mapping	NULL
(	NULL
TGEM	NULL
)	NULL
technique	NULL
described	NULL
here	NULL
provides	NULL
a	NULL
rapid	NULL
approach	NULL
for	NULL
identifying	NULL
T	NULL
cell	NULL
epitopes	NULL
of	NULL
known	NULL
Ags	NULL
,	NULL
taking	NULL
advantage	NULL
of	NULL
the	NULL
fact	NULL
that	NULL
empty	NULL
class	NULL
II	NULL
molecules	NULL
can	NULL
be	NULL
loaded	NULL
easily	NULL
with	NULL
peptides	NULL
of	NULL
interest	NULL
and	NULL
subsequently	NULL
tetramerized	NULL
.	NULL

Knowing	NULL
only	NULL
the	NULL
HLA	NULL
class	NULL
II	NULL
genotype	NULL
of	NULL
an	NULL
individual	NULL
,	NULL
it	NULL
is	NULL
feasible	NULL
to	NULL
identify	NULL
major	NULL
epitopes	NULL
of	NULL
complex	NULL
Ags	NULL
by	NULL
a	NULL
straightforward	NULL
tetramer	NULL
staining	NULL
analysis	NULL
.	NULL

As	NULL
seen	NULL
in	NULL
this	NULL
study	NULL
,	NULL
the	NULL
TGEM	NULL
protocol	NULL
discriminates	NULL
both	NULL
between	NULL
peptides	NULL
and	NULL
between	NULL
closely	NULL
related	NULL
MHC	NULL
molecules	NULL
.	NULL

Indeed	NULL
,	NULL
for	NULL
both	NULL
the	NULL
VP16	NULL
;	NULL
;	NULL
;	NULL
,	NULL
and	NULL
VP16	NULL
,	NULL
,	NULL
,	NULL
,	NULL
;	NULL
,	NULL
epitopes	NULL
presented	NULL
by	NULL
DRO401	NULL
,	NULL
TGEM	NULL
analysis	NULL
revealed	NULL
minimal	NULL
epitopes	NULL
that	NULL
were	NULL
subsequently	NULL
confirmed	NULL
by	NULL
direct	NULL
synthesis	NULL
and	NULL
testing	NULL
of	NULL
the	NULL
minimal	NULL
peptide	NULL
.	NULL

There	NULL
was	NULL
a	NULL
general	NULL
concordance	NULL
when	NULL
comparing	NULL
epitopes	NULL
identified	NULL
by	NULL
TGEM	NULL
with	NULL
those	NULL
epitopes	NULL
identified	NULL
by	NULL
IFN-y	NULL
secretion	NULL
;	NULL
however	NULL
,	NULL
some	NULL
epitopes	NULL
were	NULL
identified	NULL
only	NULL
by	NULL
one	NULL
or	NULL
the	NULL
other	NULL
method	NULL
,	NULL
likely	NULL
reflecting	NULL
the	NULL
different	NULL
T	NULL
cell	NULL
characteristics	NULL
each	NULL
approach	NULL
measures	NULL
.	NULL

Earlier	NULL
studies	NULL
examining	NULL
Ag-specific	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
with	NULL
class	NULL
I	NULL
tetramers	NULL
have	NULL
likewise	NULL
demonstrated	NULL
this	NULL
incomplete	NULL
concordance	NULL
between	NULL
Ag-specific	NULL
cytokine	NULL
production	NULL
and	NULL
tetramer	NULL
staining	NULL
(	NULL
10	NULL
,	NULL
35	NULL
)	NULL
.	NULL

The	NULL
MHC	NULL
class	NULL
II	NULL
tetramers	NULL
in	NULL
this	NULL
study	NULL
were	NULL
generated	NULL
by	NULL
using	NULL
a	NULL
peptide	NULL
mixture	NULL
.	NULL

Notably	NULL
,	NULL
the	NULL
current	NULL
results	NULL
demonstrate	NULL
that	NULL
tetramers	NULL
generated	NULL
with	NULL
peptide	NULL
mixtures	NULL
are	NULL
capable	NULL
of	NULL
staining	NULL
Ag-specific	NULL
T	NULL
cells	NULL
.	NULL

We	NULL
speculate	NULL
that	NULL
within	NULL
a	NULL
given	NULL
peptide	NULL
mixture	NULL
,	NULL
only	NULL
one	NULL
or	NULL
two	NULL
peptides	NULL
can	NULL
bind	NULL
to	NULL
the	NULL
MHC	NULL
with	NULL
high	NULL
affinity	NULL
.	NULL

These	NULL
high-affinity	NULL
peptide	NULL
complexes	NULL
likely	NULL
ensure	NULL
the	NULL
formation	NULL
of	NULL
sufficient	NULL
numbers	NULL
of	NULL
tetramers	NULL
containing	NULL
identical	NULL
MHC/peptide	NULL
complexes	NULL
.	NULL

Data	NULL
from	NULL
our	NULL
laboratory	NULL
and	NULL
others	NULL
suggests	NULL
that	NULL
10-50	NULL
%	NULL
of	NULL
the	NULL
soluble	NULL
MHC	NULL
molecules	NULL
are	NULL
loaded	NULL
when	NULL
incubated	NULL
with	NULL
exogenous	NULL
peptide	NULL
(	NULL
Ref	NULL
.	NULL

36	NULL
and	NULL
W.	NULL
Kwok	NULL
,	NULL
B.	NULL
McFarland	NULL
,	NULL
C.	NULL
Beeson	NULL
,	NULL
unpublished	NULL
observations	NULL
)	NULL
.	NULL

Applying	NULL
these	NULL
observations	NULL
to	NULL
tetrameric	NULL
molecules	NULL
suggests	NULL
that	NULL
with	NULL
exogenous	NULL
peptide	NULL
loading	NULL
,	NULL
less	NULL
than	NULL
6	NULL
%	NULL
of	NULL
the	NULL
tetramers	NULL
have	NULL
all	NULL
four	NULL
MHC	NULL
molecules	NULL
loaded	NULL
with	NULL
peptide	NULL
,	NULL
assuming	NULL
a	NULL
lack	NULL
of	NULL
cooperative	NULL
interactions	NULL
.	NULL

Staining	NULL
with	NULL
dimeric	NULL
or	NULL
trimeric	NULL
MHC/peptide	NULL
complexes	NULL
previously	NULL
has	NULL
been	NULL
reported	NULL
(	NULL
37	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
T	NULL
cell	NULL
staining	NULL
observed	NULL
in	NULL
our	NULL
study	NULL
is	NULL
likely	NULL
at	NULL
least	NULL
partly	NULL
attributable	NULL
to	NULL
binding	NULL
of	NULL
MHC	NULL
tetramer	NULL
complexes	NULL
with	NULL
only	NULL
two	NULL
or	NULL
three	NULL
sites	NULL
occupied	NULL
by	NULL
the	NULL
cognate	NULL
peptide	NULL
.	NULL

One	NULL
of	NULL
the	NULL
concerns	NULL
of	NULL
the	NULL
TGEM	NULL
approach	NULL
is	NULL
that	NULL
the	NULL
relevant	NULL
peptides	NULL
will	NULL
be	NULL
outcompeted	NULL
by	NULL
irrelevant	NULL
peptides	NULL
present	NULL
in	NULL
the	NULL
pool	NULL
.	NULL

For	NULL
this	NULL
reason	NULL
,	NULL
we	NULL
purposefully	NULL
loaded	NULL
DRO401	NULL
molecules	NULL
with	NULL
different	NULL
molar	NULL
ratios	NULL
of	NULL
cognate	NULL
peptide	NULL
(	NULL
VP16	NULL
p61	NULL
)	NULL
to	NULL
competitor	NULL
peptide	NULL
(	NULL
HA	NULL
;	NULL
,	NULL
,	NULL
;	NULL
,9	NULL
)	NULL
,	NULL
and	NULL
these	NULL
mixed	NULL
tetramers	NULL
were	NULL
used	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
Control	NULL
Tetramer	NULL
6669	NULL
Specific	NULL
Tetramer	NULL
(	NULL
Nr	NULL
Z	NULL
D	NULL
»	NULL
_	NULL
p61-1	NULL
06	NULL
%	NULL
__	NULL
»	NULL
p61-1	NULL
99.7	NULL
%	NULL
_	NULL
»	NULL
p61-2	NULL
_	NULL
994	NULL
%	NULL
s	NULL
p61-3	NULL
_	NULL
994	NULL
%	NULL
A	NULL
-	NULL
-	NULL
75000	NULL
&	NULL
&	NULL
&	NULL
&	NULL
wile	NULL
2	NULL
]	NULL
S	NULL
S	NULL
&	NULL
%	NULL
50000	NULL
A	NULL
>	NULL
»	NULL
»	NULL
B	NULL
t	NULL
p	NULL
10	NULL
0	NULL
e	NULL
e	NULL
a	NULL
e	NULL
25000	NULL
P	NULL
P	NULL
&	NULL
P	NULL
10°	NULL
10°	NULL
10°	NULL
10	NULL
o	NULL
10	NULL
10	NULL
10°	NULL
10	NULL
10	NULL
10	NULL
10	NULL
10°	NULL
10°	NULL
10	NULL
10	NULL
10	NULL
10°	NULL
{	NULL
161-1	NULL
p61-2	NULL
[	NULL
161—3	NULL
»	NULL
_	NULL
p58-1	NULL
0.1	NULL
%	NULL
a	NULL
pS58-1	NULL
97.4	NULL
%	NULL
»	NULL
_	NULL
p58-2	NULL
98.5	NULL
%	NULL
»	NULL
p58-3	NULL
96.6	NULL
%	NULL
.	NULL

7	NULL
t	NULL
-	NULL
75000	NULL
g	NULL
a	NULL
a	NULL
®	NULL
e	NULL
50000	NULL
S	NULL
'	NULL
B	NULL
s	NULL
®	NULL
®	NULL
»	NULL
E	NULL
S	NULL
2	NULL
]	NULL
&	NULL
8	NULL
]	NULL
&	NULL
0	NULL
.	NULL

o	NULL
i-	NULL
s	NULL
s	NULL
s	NULL
B	NULL
-	NULL
25000	NULL
B	NULL
&	NULL
&	NULL
10°	NULL
10	NULL
``	NULL
10	NULL
10	NULL
10°	NULL
10°	NULL
10	NULL
10	NULL
``	NULL
10°	NULL
10	NULL
10°	NULL
10	NULL
10	NULL
'	NULL
10	NULL
10	NULL
10°	NULL
{	NULL
358-1	NULL
p58~2	NULL
[	NULL
158—3	NULL
»	NULL
_	NULL
p10-1	NULL
0.7	NULL
%	NULL
»	NULL
p10-1	NULL
88.2	NULL
%	NULL
b	NULL
»	NULL
-	NULL
p10-3	NULL
6.9	NULL
%	NULL
~	NULL
~	NULL
-	NULL
200000	NULL
&	NULL
&	NULL
&	NULL
&	NULL
3	NULL
2	NULL
]	NULL
€	NULL
]	NULL
a	NULL
150000	NULL
=	NULL
C	NULL
#	NULL
®	NULL
®	NULL
®	NULL
&	NULL
-	NULL
&	NULL
100000	NULL
e	NULL
6	NULL
&	NULL
2	NULL
]	NULL
50000	NULL
P	NULL
&	NULL
P	NULL
&	NULL
0	NULL
10	NULL
_	NULL
10	NULL
19	NULL
doo	NULL
40	NULL
7¢	NULL
o	NULL
10	NULL
1d	NULL
ad	NULL
P	NULL
ar	NULL
1G	NULL
p10-1	NULL
p10-2	NULL
p10-3	NULL
FIGURE	NULL
4	NULL
.	NULL

-	NULL
Specificity	NULL
of	NULL
DRO401-	NULL
and	NULL
DRO404-restricted	NULL
T	NULL
cell	NULL
clones	NULL
.	NULL

Ag	NULL
specificities	NULL
of	NULL
T	NULL
cells	NULL
clones	NULL
obtained	NULL
by	NULL
cell	NULL
sorting	NULL
were	NULL
reconfirmed	NULL
by	NULL
both	NULL
tetramer	NULL
staining	NULL
and	NULL
peptide-dependent	NULL
proliferation	NULL
.	NULL

Three	NULL
clones	NULL
specific	NULL
for	NULL
(	NULL
A	NULL
)	NULL
DRO401/p61	NULL
,	NULL
(	NULL
B	NULL
)	NULL
DRO404/p58	NULL
,	NULL
and	NULL
(	NULL
C	NULL
)	NULL
DRO401/p10	NULL
are	NULL
shown	NULL
.	NULL

Staining	NULL
with	NULL
tetramer	NULL
loaded	NULL
with	NULL
HAsy	NULL
;	NULL
319	NULL
is	NULL
shown	NULL
as	NULL
a	NULL
control	NULL
in	NULL
the	NULL
left	NULL
panel	NULL
for	NULL
one	NULL
of	NULL
the	NULL
clones	NULL
.	NULL

Specific	NULL
tetramer	NULL
staining	NULL
is	NULL
shown	NULL
for	NULL
each	NULL
clone	NULL
in	NULL
the	NULL
center	NULL
columns	NULL
.	NULL

Percentages	NULL
indicate	NULL
the	NULL
percent	NULL
of	NULL
cells	NULL
in	NULL
the	NULL
upper	NULL
right	NULL
quadrant	NULL
.	NULL

The	NULL
right	NULL
panel	NULL
shows	NULL
72-h	NULL
[	NULL
*°H|thymidine	NULL
incorporation	NULL
with	NULL
BLS-DRO401	NULL
(	NULL
A	NULL
and	NULL
C	NULL
)	NULL
or	NULL
BLS-DRO404	NULL
(	NULL
B	NULL
)	NULL
as	NULL
APCs	NULL
without	NULL
peptide	NULL
(	NULL
light	NULL
shading	NULL
)	NULL
and	NULL
with	NULL
10	NULL
pg/ml	NULL
specific	NULL
peptide	NULL
(	NULL
dark	NULL
shading	NULL
)	NULL
.	NULL

to	NULL
stain	NULL
a	NULL
DRO401/p61	NULL
clone	NULL
.	NULL

In	NULL
competition	NULL
experiments	NULL
,	NULL
these	NULL
two	NULL
peptides	NULL
possess	NULL
similar	NULL
affinities	NULL
for	NULL
the	NULL
DRO401	NULL
molecule	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

There	NULL
was	NULL
no	NULL
significant	NULL
difference	NULL
in	NULL
staining	NULL
pattern	NULL
when	NULL
the	NULL
molar	NULL
ratio	NULL
of	NULL
p61	NULL
to	NULL
HAzq	NULL
;	NULL
319	NULL
was	NULL
1:1	NULL
.	NULL

We	NULL
observed	NULL
an	NULL
appreciable	NULL
decrease	NULL
in	NULL
staining	NULL
intensity	NULL
of	NULL
the	NULL
DRO401/p61	NULL
clone	NULL
with	NULL
a	NULL
1:10	NULL
molar	NULL
ratio	NULL
;	NULL
nonetheless	NULL
,	NULL
staining	NULL
of	NULL
clones	NULL
with	NULL
these	NULL
mixed	NULL
tetramers	NULL
was	NULL
still	NULL
10-fold	NULL
above	NULL
background	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Likewise	NULL
,	NULL
we	NULL
were	NULL
able	NULL
to	NULL
obtain	NULL
similar	NULL
staining	NULL
above	NULL
background	NULL
by	NULL
using	NULL
cognate	NULL
tetramer	NULL
diluted	NULL
100-fold	NULL
,	NULL
suggesting	NULL
that	NULL
an	NULL
excess	NULL
of	NULL
class	NULL
II	NULL
molecules	NULL
are	NULL
present	NULL
during	NULL
the	NULL
staining	NULL
reaction	NULL
.	NULL

These	NULL
findings	NULL
suggest	NULL
that	NULL
loading	NULL
of	NULL
peptide	NULL
mixtures	NULL
onto	NULL
class	NULL
II	NULL
within	NULL
the	NULL
parameters	NULL
described	NULL
should	NULL
not	NULL
preclude	NULL
the	NULL
TGEM	NULL
approach	NULL
from	NULL
detecting	NULL
Ag-specific	NULL
T	NULL
cells	NULL
of	NULL
interest	NULL
.	NULL

Earlier	NULL
studies	NULL
that	NULL
used	NULL
pooled	NULL
peptides	NULL
to	NULL
stimulate	NULL
cells	NULL
have	NULL
shown	NULL
similar	NULL
results	NULL
(	NULL
25	NULL
,	NULL
26	NULL
,	NULL
38	NULL
)	NULL
,	NULL
and	NULL
studies	NULL
that	NULL
used	NULL
combinatorial	NULL
peptide	NULL
libraries	NULL
have	NULL
demonstrated	NULL
that	NULL
HLA	NULL
competition	NULL
only	NULL
becomes	NULL
a	NULL
contributing	NULL
factor	NULL
in	NULL
T	NULL
cell	NULL
stimulation	NULL
when	NULL
competitor	NULL
peptides	NULL
are	NULL
present	NULL
in	NULL
several	NULL
orders	NULL
of	NULL
magnitude	NULL
excess	NULL
(	NULL
39	NULL
)	NULL
.	NULL

Nonetheless	NULL
,	NULL
it	NULL
is	NULL
conceivable	NULL
that	NULL
the	NULL
pooled	NULL
peptide	NULL
approach	NULL
may	NULL
have	NULL
difficulty	NULL
in	NULL
detecting	NULL
peptide	NULL
epitopes	NULL
with	NULL
very	NULL
low	NULL
MHC	NULL
binding	NULL
affinity	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
other	NULL
peptides	NULL
in	NULL
the	NULL
same	NULL
peptide	NULL
pool	NULL
with	NULL
high	NULL
MHC	NULL
binding	NULL
affinity	NULL
.	NULL

The	NULL
standard	NULL
approach	NULL
for	NULL
cloning	NULL
T	NULL
cells	NULL
and	NULL
mapping	NULL
out	NULL
antigenic	NULL
epitopes	NULL
involves	NULL
Ag	NULL
challenge	NULL
of	NULL
PBMC	NULL
followed	NULL
by	NULL
plating	NULL
individual	NULL
cells	NULL
into	NULL
96-well	NULL
plates	NULL
.	NULL

Cells	NULL
then	NULL
are	NULL
expanded	NULL
and	NULL
assayed	NULL
for	NULL
MHC	NULL
restriction	NULL
and	NULL
peptide	NULL
specificities	NULL
by	NULL
screening	NULL
clones	NULL
with	NULL
overlapping	NULL
peptides	NULL
that	NULL
cover	NULL
the	NULL
Ag	NULL
,	NULL
a	NULL
labor-intensive	NULL
and	NULL
time-consuming	NULL
process	NULL
.	NULL

Alternatively	NULL
,	NULL
epitopes	NULL
can	NULL
be	NULL
identified	NULL
by	NULL
using	NULL
a	NULL
recently	NULL
described	NULL
flow	NULL
cy-tometry-based	NULL
approach	NULL
that	NULL
uses	NULL
IFN-y	NULL
production	NULL
as	NULL
a	NULL
marker	NULL
of	NULL
reactivity	NULL
.	NULL

Although	NULL
this	NULL
approach	NULL
simplifies	NULL
isolation	NULL
of	NULL
epitope-specific	NULL
clones	NULL
,	NULL
the	NULL
task	NULL
of	NULL
identifying	NULL
individual	NULL
MHC	NULL
restriction	NULL
elements	NULL
remains	NULL
.	NULL

With	NULL
TGEM	NULL
,	NULL
the	NULL
HLA	NULL
restriction	NULL
and	NULL
peptide	NULL
specificity	NULL
of	NULL
the	NULL
T	NULL
cells	NULL
are	NULL
known	NULL
because	NULL
of	NULL
the	NULL
specificity	NULL
of	NULL
tetramer	NULL
staining	NULL
.	NULL

Tetramer	NULL
staining	NULL
also	NULL
offers	NULL
the	NULL
opportunity	NULL
for	NULL
straightforward	NULL
cloning	NULL
of	NULL
the	NULL
Ag-specific	NULL
T	NULL
cells	NULL
through	NULL
single-cell	NULL
sorting	NULL
.	NULL

As	NULL
a	NULL
consequence	NULL
,	NULL
large	NULL
numbers	NULL
of	NULL
T	NULL
cells	NULL
clones	NULL
with	NULL
known	NULL
Ag	NULL
specificities	NULL
and	NULL
MHC	NULL
restrictions	NULL
can	NULL
be	NULL
obtained	NULL
easily	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
have	NULL
found	NULL
that	NULL
the	NULL
Ag-dependent	NULL
expansion	NULL
of	NULL
T	NULL
cells	NULL
in	NULL
the	NULL
TGEM	NULL
procedure	NULL
can	NULL
be	NULL
performed	NULL
without	NULL
purified	NULL
Ag	NULL
.	NULL

For	NULL
assay	NULL
of	NULL
viral	NULL
antigenic	NULL
epitopes	NULL
,	NULL
we	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
stimulation	NULL
with	NULL
UV-inactivated	NULL
virus	NULL
is	NULL
effective	NULL
Table	NULL
I	NULL
.	NULL

Relative	NULL
binding	NULL
affinity	NULL
of	NULL
DRO4O01-	NULL
and	NULL
DRO404-restricted	NULL
VP16	NULL
epitopes	NULL
``	NULL
ICs	NULL
,	NULL
0401	NULL
_	NULL
ICs	NULL
,	NULL
0404	NULL
(	NULL
uM	NULL
)	NULL
(	NULL
uM	NULL
)	NULL
DRO401-restricted	NULL
VP16	NULL
epitopes	NULL
:	NULL
VP16sg	NULL
45	NULL
ALENRLLDDLGF	NULL
2	NULL
4	NULL
VP16	NULL
,	NULL
;	NULL
,	NULL
43	NULL
,	NULL
DFEFEQMFTDAMG	NULL
0.5	NULL
0.5	NULL
DRO404-restricted	NULL
VP16	NULL
epitopes	NULL
:	NULL
VP16	NULL
,	NULL
,	NULL
,	NULL
455	NULL
FDLEMLGDVESPS	NULL
>	NULL
5	NULL
0.005	NULL
``	NULL
Underlined	NULL
residue	NULL
is	NULL
the	NULL
proposed	NULL
first	NULL
anchor	NULL
for	NULL
binding	NULL
to	NULL
the	NULL
respective	NULL
allele	NULL
as	NULL
determined	NULL
by	NULL
peptide	NULL
truncation	NULL
studies	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
6670	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
peptide	NULL
pools	NULL
can	NULL
be	NULL
used	NULL
for	NULL
initial	NULL
stimulation	NULL
in	NULL
the	NULL
event	NULL
that	NULL
whole	NULL
Ag	NULL
is	NULL
not	NULL
available	NULL
.	NULL

Knowledge	NULL
of	NULL
specific	NULL
Ag	NULL
epitopes	NULL
and	NULL
their	NULL
associated	NULL
MHC	NULL
restrictions	NULL
provides	NULL
a	NULL
valuable	NULL
foundation	NULL
for	NULL
directed	NULL
immuno-therapies	NULL
in	NULL
a	NULL
number	NULL
of	NULL
different	NULL
areas	NULL
including	NULL
autoimmune	NULL
and	NULL
infectious	NULL
diseases	NULL
and	NULL
cancer	NULL
(	NULL
1-5	NULL
)	NULL
.	NULL

TGEM	NULL
allows	NULL
rapid	NULL
identification	NULL
of	NULL
CD4	NULL
*	NULL
T	NULL
cell	NULL
epitopes	NULL
and	NULL
can	NULL
easily	NULL
be	NULL
applied	NULL
to	NULL
a	NULL
variety	NULL
of	NULL
Ags	NULL
,	NULL
especially	NULL
as	NULL
tetramer	NULL
reagents	NULL
become	NULL
more	NULL
widely	NULL
available	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
Susan	NULL
Masewicz	NULL
,	NULL
Lori	NULL
Moriarity	NULL
,	NULL
and	NULL
Sharon	NULL
Kochik	NULL
for	NULL
expert	NULL
technical	NULL
assistance	NULL
.	NULL

References	NULL
1	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

Chang	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
N.	NULL
H.	NULL
Gruener	NULL
,	NULL
S.	NULL
Southwood	NULL
,	NULL
J.	NULL
Sidney	NULL
,	NULL
G.	NULL
R.	NULL
Pape	NULL
,	NULL
F.	NULL
V.	NULL
Chisari	NULL
,	NULL
and	NULL
A.	NULL
Sette	NULL
.	NULL

1999	NULL
.	NULL

Identification	NULL
of	NULL
HLA-A3	NULL
and	NULL
-B7-restricted	NULL
CTL	NULL
response	NULL
to	NULL
hepatitis	NULL
C	NULL
virus	NULL
in	NULL
patients	NULL
with	NULL
acute	NULL
and	NULL
chronic	NULL
hepatitis	NULL
C.	NULL
J.	NULL
Immunol	NULL
.	NULL

162:1156.	NULL
.	NULL

Rolland	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
R.	NULL
O'Hehir	NULL
.	NULL

1998	NULL
.	NULL

Immunotherapy	NULL
of	NULL
allergy	NULL
:	NULL
anergy	NULL
,	NULL
deletion	NULL
,	NULL
and	NULL
immune	NULL
deviation	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

10:640.	NULL
.	NULL

Wicker	NULL
,	NULL
L.	NULL
S.	NULL
,	NULL
S.	NULL
L.	NULL
Chen	NULL
,	NULL
G.	NULL
T.	NULL
Nepom	NULL
,	NULL
J.	NULL
F.	NULL
Elliott	NULL
,	NULL
D.	NULL
C.	NULL
Freed	NULL
,	NULL
A.	NULL
Bansal	NULL
,	NULL
S.	NULL
Zheng	NULL
,	NULL
A.	NULL
Herman	NULL
,	NULL
A.	NULL
Lernmark	NULL
,	NULL
D.	NULL
M.	NULL
Zaller	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
.	NULL

Naturally	NULL
processed	NULL
T	NULL
cell	NULL
epitopes	NULL
from	NULL
human	NULL
glutamic	NULL
acid	NULL
decarboxylase	NULL
identified	NULL
using	NULL
mice	NULL
transgenic	NULL
for	NULL
the	NULL
type	NULL
1	NULL
diabetes-associated	NULL
human	NULL
MHC	NULL
class	NULL
II	NULL
allele	NULL
,	NULL
DRB1*0401	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

98:2597.	NULL
.	NULL

Falk	NULL
,	NULL
K.	NULL
,	NULL
O.	NULL
Rotzschke	NULL
,	NULL
L.	NULL
Santambrogio	NULL
,	NULL
M.	NULL
E.	NULL
Dorf	NULL
,	NULL
C.	NULL
Brosnan	NULL
,	NULL
and	NULL
J.	NULL
L.	NULL
Strominger	NULL
.	NULL

2000	NULL
.	NULL

Induction	NULL
and	NULL
suppression	NULL
of	NULL
an	NULL
autoimmune	NULL
disease	NULL
by	NULL
oligomerized	NULL
T	NULL
cell	NULL
epitopes	NULL
:	NULL
enhanced	NULL
in	NULL
vivo	NULL
potency	NULL
of	NULL
encephalitogenic	NULL
peptides	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

191:717.	NULL
.	NULL

Wang	NULL
,	NULL
R.	NULL
F.	NULL
,	NULL
and	NULL
S.	NULL
A.	NULL
Rosenberg	NULL
.	NULL

1999	NULL
.	NULL

Human	NULL
tumor	NULL
antigens	NULL
for	NULL
cancer	NULL
vaccine	NULL
development	NULL
.	NULL

Immunol	NULL
.	NULL

Rev	NULL
.	NULL

170:85.	NULL
.	NULL

Altman	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
P.	NULL
A.	NULL
H.	NULL
Moss	NULL
,	NULL
P.	NULL
J.	NULL
R.	NULL
Goulder	NULL
,	NULL
D.	NULL
H.	NULL
Barouch	NULL
,	NULL
M.	NULL
G.	NULL
McHeyzer-Williams	NULL
,	NULL
J.	NULL
I	NULL
.	NULL

Bell	NULL
,	NULL
A.	NULL
J.	NULL
McMichael	NULL
,	NULL
and	NULL
M.	NULL
M.	NULL
Davis	NULL
.	NULL

1996	NULL
.	NULL

Phenotypic	NULL
analysis	NULL
of	NULL
antigen-specific	NULL
T	NULL
lymphocytes	NULL
.	NULL

Science	NULL
274:94.	NULL
.	NULL

Callan	NULL
,	NULL
M.	NULL
F.	NULL
,	NULL
L.	NULL
Tan	NULL
,	NULL
N.	NULL
Annels	NULL
,	NULL
G.	NULL
S.	NULL
Ogg	NULL
,	NULL
J.	NULL
D.	NULL
Wilson	NULL
,	NULL
C.	NULL
A.	NULL
O'Callaghan	NULL
,	NULL
N.	NULL
Steven	NULL
,	NULL
A.	NULL
J.	NULL
McMichael	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
.	NULL

1998	NULL
.	NULL

Direct	NULL
visualization	NULL
of	NULL
antigen-specific	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
during	NULL
the	NULL
primary	NULL
immune	NULL
response	NULL
to	NULL
Epstein-Barr	NULL
virus	NULL
in	NULL
vivo	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

187:1395.	NULL
.	NULL

Gallimore	NULL
,	NULL
A.	NULL
,	NULL
A.	NULL
Glithero	NULL
,	NULL
A.	NULL
Godkin	NULL
,	NULL
A.	NULL
C.	NULL
Tissot	NULL
,	NULL
A.	NULL
Pluckthun	NULL
,	NULL
T.	NULL
Elliott	NULL
,	NULL
H.	NULL
Hengartner	NULL
,	NULL
and	NULL
R.	NULL
Zinkernagel	NULL
.	NULL

1998	NULL
.	NULL

Induction	NULL
and	NULL
exhaustion	NULL
of	NULL
lympho-cytic	NULL
choriomeningitis	NULL
virus-specific	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
visualized	NULL
using	NULL
soluble	NULL
tetrameric	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
I-peptide	NULL
complexes	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

187:1383.	NULL
.	NULL

Wilson	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
G.	NULL
S.	NULL
Ogg	NULL
,	NULL
R.	NULL
L.	NULL
Allen	NULL
,	NULL
P.	NULL
J.	NULL
Goulder	NULL
,	NULL
A.	NULL
Kelleher	NULL
,	NULL
A.	NULL
K.	NULL
Sewell	NULL
,	NULL
C.	NULL
A.	NULL
O'Callaghan	NULL
,	NULL
S.	NULL
L.	NULL
Rowland-Jones	NULL
,	NULL
M.	NULL
F.	NULL
Callan	NULL
,	NULL
and	NULL
A.	NULL
J.	NULL
McMichael	NULL
.	NULL

1998	NULL
.	NULL

Oligoclonal	NULL
expansions	NULL
of	NULL
CD8*	NULL
T	NULL
cells	NULL
in	NULL
chronic	NULL
HIV	NULL
infection	NULL
are	NULL
antigen	NULL
specific	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

188:785	NULL
.	NULL

Lee	NULL
,	NULL
P.	NULL
P.	NULL
,	NULL
C.	NULL
Yee	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

Savage	NULL
,	NULL
L.	NULL
Fong	NULL
,	NULL
D.	NULL
Brockstedt	NULL
,	NULL
J.	NULL
S.	NULL
Weber	NULL
,	NULL
D.	NULL
Johnson	NULL
,	NULL
S.	NULL
Swetter	NULL
,	NULL
J.	NULL
Thompson	NULL
,	NULL
P.	NULL
D.	NULL
Greenberg	NULL
,	NULL
M.	NULL
Roederer	NULL
,	NULL
and	NULL
M.	NULL
M.	NULL
Davis	NULL
.	NULL

1999	NULL
.	NULL

Characterization	NULL
of	NULL
circulating	NULL
T	NULL
cells	NULL
specific	NULL
for	NULL
tumor-associated	NULL
antigens	NULL
in	NULL
melanoma	NULL
patients	NULL
.	NULL

Nat	NULL
.	NULL

Med	NULL
.	NULL

5:677	NULL
.	NULL

Pittet	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
D.	NULL
Valmori	NULL
,	NULL
P.	NULL
R.	NULL
Dunbar	NULL
,	NULL
D.	NULL
E.	NULL
Speiser	NULL
,	NULL
D.	NULL
Lienard	NULL
,	NULL
F.	NULL
Lejeune	NULL
,	NULL
K.	NULL
Fleischhauer	NULL
,	NULL
V.	NULL
Cerundolo	NULL
,	NULL
J.	NULL
C.	NULL
Cerottini	NULL
,	NULL
and	NULL
P.	NULL
Romero	NULL
.	NULL

1999	NULL
.	NULL

High	NULL
frequencies	NULL
of	NULL
naive	NULL
Melan-A/MART-1-specific	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
in	NULL
a	NULL
large	NULL
proportion	NULL
of	NULL
human	NULL
histocompatibility	NULL
leukocyte	NULL
antigen	NULL
(	NULL
HLA	NULL
)	NULL
-A2	NULL
individuals	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

190:705	NULL
.	NULL

Dunbar	NULL
,	NULL
P.	NULL
R.	NULL
,	NULL
J.	NULL
L.	NULL
Chen	NULL
,	NULL
D.	NULL
Chao	NULL
,	NULL
N.	NULL
Rust	NULL
,	NULL
H.	NULL
Teisserenc	NULL
,	NULL
G.	NULL
S.	NULL
Ogg	NULL
,	NULL
P.	NULL
Romero	NULL
,	NULL
P.	NULL
Weynants	NULL
,	NULL
and	NULL
V.	NULL
Cerundolo	NULL
.	NULL

1999	NULL
.	NULL

Cutting	NULL
edge	NULL
:	NULL
rapid	NULL
cloning	NULL
of	NULL
tumor-specific	NULL
CTL	NULL
suitable	NULL
for	NULL
adoptive	NULL
immunotherapy	NULL
of	NULL
melanoma	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

162:6959	NULL
.	NULL

Molldrem	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
P.	NULL
P.	NULL
Lee	NULL
,	NULL
C.	NULL
Wang	NULL
,	NULL
R.	NULL
E.	NULL
Champlin	NULL
,	NULL
and	NULL
M.	NULL
M.	NULL
Davis	NULL
.	NULL

1999	NULL
.	NULL

A	NULL
PR1-human	NULL
leukocyte	NULL
antigen-A2	NULL
tetramer	NULL
can	NULL
be	NULL
used	NULL
to	NULL
isolate	NULL
low-	NULL
frequency	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
from	NULL
healthy	NULL
donors	NULL
that	NULL
selectively	NULL
lyse	NULL
chronic	NULL
my-elogenous	NULL
leukemia	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

59:2675	NULL
.	NULL

Crawford	NULL
,	NULL
F.	NULL
,	NULL
H.	NULL
Kozono	NULL
,	NULL
J	NULL
.	NULL

White	NULL
,	NULL
P.	NULL
Marrack	NULL
,	NULL
and	NULL
J.	NULL
Kappler	NULL
.	NULL

1998	NULL
.	NULL

Detection	NULL
of	NULL
antigen-specific	NULL
T	NULL
cells	NULL
with	NULL
multivalent	NULL
soluble	NULL
class	NULL
II	NULL
MHC	NULL
covalent	NULL
peptide	NULL
complexes	NULL
.	NULL

Immunity	NULL
8:675	NULL
.	NULL

Kotzin	NULL
,	NULL
B.	NULL
L.	NULL
,	NULL
M.	NULL
T.	NULL
Falta	NULL
,	NULL
F.	NULL
Crawford	NULL
,	NULL
E.	NULL
F.	NULL
Rosloniec	NULL
,	NULL
J	NULL
.	NULL

Bill	NULL
,	NULL
P.	NULL
Marrack	NULL
,	NULL
and	NULL
J.	NULL
Kappler	NULL
.	NULL

2000	NULL
.	NULL

Use	NULL
of	NULL
soluble	NULL
peptide-DR4	NULL
tetramers	NULL
to	NULL
detect	NULL
synovial	NULL
T	NULL
cells	NULL
specific	NULL
for	NULL
cartilage	NULL
antigens	NULL
in	NULL
patients	NULL
with	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
97:291	NULL
.	NULL

Gutgemann	NULL
,	NULL
I.	NULL
,	NULL
A.	NULL
M.	NULL
Fahrer	NULL
,	NULL
J.	NULL
D.	NULL
Altman	NULL
,	NULL
M.	NULL
M.	NULL
Davis	NULL
,	NULL
and	NULL
Y.	NULL
H.	NULL
Chien	NULL
.	NULL

1998	NULL
.	NULL

Induction	NULL
of	NULL
rapid	NULL
T	NULL
cell	NULL
activation	NULL
and	NULL
tolerance	NULL
by	NULL
systemic	NULL
presentation	NULL
of	NULL
an	NULL
orally	NULL
administered	NULL
antigen	NULL
.	NULL

Immunity	NULL
8:667	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

TETRAMER-GUIDED	NULL
EPITOPE	NULL
MAPPING	NULL
(	NULL
TGEM	NULL
)	NULL
Savage	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
J.	NULL
J.	NULL
Boniface	NULL
,	NULL
and	NULL
M.	NULL
M.	NULL
Davis	NULL
.	NULL

1999	NULL
.	NULL

A	NULL
kinetic	NULL
basis	NULL
for	NULL
T	NULL
cell	NULL
receptor	NULL
repertoire	NULL
selection	NULL
during	NULL
an	NULL
immune	NULL
response	NULL
.	NULL

Immunity	NULL
10:485	NULL
.	NULL

Novak	NULL
,	NULL
E.	NULL
J.	NULL
,	NULL
A.	NULL
W.	NULL
Liu	NULL
,	NULL
G.	NULL
T.	NULL
Nepom	NULL
,	NULL
and	NULL
W.	NULL
W.	NULL
Kwok	NULL
.	NULL

1999	NULL
.	NULL

MHC	NULL
class	NULL
II	NULL
tetramers	NULL
identify	NULL
peptide-specific	NULL
human	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
proliferating	NULL
in	NULL
response	NULL
to	NULL
influenza	NULL
A	NULL
antigen	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

104	NULL
:	NULL
R63	NULL
.	NULL

Kwok	NULL
,	NULL
W.	NULL
W.	NULL
,	NULL
A.	NULL
W.	NULL
Liu	NULL
,	NULL
E.	NULL
J.	NULL
Novak	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Gebe	NULL
,	NULL
R.	NULL
A.	NULL
Ettinger	NULL
,	NULL
G.	NULL
T.	NULL
Nepom	NULL
,	NULL
S.	NULL
N.	NULL
Reymond	NULL
,	NULL
and	NULL
D.	NULL
M.	NULL
Koelle	NULL
.	NULL

2000	NULL
.	NULL

HLA-DQ	NULL
tetramers	NULL
identify	NULL
epitope-specific	NULL
T	NULL
cells	NULL
in	NULL
peripheral	NULL
blood	NULL
of	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
2-infected	NULL
indi-viduals	NULL
:	NULL
direct	NULL
detection	NULL
of	NULL
immunodominant	NULL
antigen-responsive	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

164:4244	NULL
.	NULL

Koelle	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
L.	NULL
Corey	NULL
,	NULL
R.	NULL
L.	NULL
Burke	NULL
,	NULL
R.	NULL
J.	NULL
Eisenberg	NULL
,	NULL
G.	NULL
H.	NULL
Cohen	NULL
,	NULL
R.	NULL
Pichyangkura	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Triezenberg	NULL
.	NULL

1994	NULL
.	NULL

Antigenic	NULL
specificities	NULL
of	NULL
human	NULL
CD4*	NULL
T-cell	NULL
clones	NULL
recovered	NULL
from	NULL
recurrent	NULL
genital	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
2	NULL
lesions	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:2803	NULL
.	NULL

Koelle	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
J.	NULL
M.	NULL
Frank	NULL
,	NULL
M.	NULL
L.	NULL
Johnson	NULL
,	NULL
and	NULL
W.	NULL
W.	NULL
Kwok	NULL
.	NULL

1998	NULL
.	NULL

Recognition	NULL
of	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
2	NULL
tegument	NULL
proteins	NULL
by	NULL
CD4	NULL
T	NULL
cells	NULL
infiltrating	NULL
human	NULL
genital	NULL
herpes	NULL
lesions	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

72:7476	NULL
.	NULL

Horton	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
Z.	NULL
L.	NULL
Cai	NULL
,	NULL
S.	NULL
N.	NULL
Ho	NULL
,	NULL
and	NULL
L.	NULL
R.	NULL
Pease	NULL
.	NULL

1990	NULL
.	NULL

Gene	NULL
splicing	NULL
by	NULL
overlap	NULL
extension	NULL
:	NULL
tailor-made	NULL
genes	NULL
using	NULL
the	NULL
polymerase	NULL
chain	NULL
reaction	NULL
.	NULL

Bio-Techniques	NULL
8:528	NULL
.	NULL

Chang	NULL
,	NULL
H.	NULL
C.	NULL
,	NULL
Z.	NULL
Bao	NULL
,	NULL
Y.	NULL
Yao	NULL
,	NULL
A.	NULL
G.	NULL
Tse	NULL
,	NULL
E.	NULL
C.	NULL
Goyarts	NULL
,	NULL
M.	NULL
Madsen	NULL
,	NULL
E.	NULL
Kawasaki	NULL
,	NULL
P.	NULL
P.	NULL
Brauer	NULL
,	NULL
J.	NULL
C.	NULL
Sacchettini	NULL
,	NULL
and	NULL
S.	NULL
G.	NULL
Nathenson	NULL
.	NULL

1994	NULL
.	NULL

A	NULL
general	NULL
method	NULL
for	NULL
facilitating	NULL
heterodimeric	NULL
pairing	NULL
between	NULL
two	NULL
proteins	NULL
:	NULL
application	NULL
to	NULL
expression	NULL
of	NULL
a	NULL
and	NULL
B	NULL
T-cell	NULL
receptor	NULL
extracellular	NULL
segments	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:11408	NULL
.	NULL

Schatz	NULL
,	NULL
P.	NULL
J	NULL
.	NULL

1993	NULL
.	NULL

Use	NULL
of	NULL
peptide	NULL
libraries	NULL
to	NULL
map	NULL
the	NULL
substrate	NULL
specificity	NULL
of	NULL
a	NULL
peptide-modifying	NULL
enzyme	NULL
:	NULL
a	NULL
13	NULL
residue	NULL
consensus	NULL
peptide	NULL
specifies	NULL
biotinylation	NULL
in	NULL
Escherichia	NULL
coli	NULL
.	NULL

Biotechnology	NULL
11:1138	NULL
.	NULL

Kern	NULL
,	NULL
F.	NULL
,	NULL
I.	NULL
P.	NULL
Surel	NULL
,	NULL
C.	NULL
Brock	NULL
,	NULL
B.	NULL
Freistedt	NULL
,	NULL
H.	NULL
Radtke	NULL
,	NULL
A.	NULL
Scheffold	NULL
,	NULL
R.	NULL
Blasezyk	NULL
,	NULL
P.	NULL
Reinke	NULL
,	NULL
J.	NULL
Schneider-Mergener	NULL
,	NULL
A.	NULL
Radbruch	NULL
,	NULL
P.	NULL
Walden	NULL
,	NULL
and	NULL
H.	NULL
D.	NULL
Volk	NULL
.	NULL

1998	NULL
.	NULL

T-cell	NULL
epitope	NULL
mapping	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Nat	NULL
.	NULL

Med	NULL
.	NULL

4:975	NULL
.	NULL

Kem	NULL
,	NULL
F.	NULL
,	NULL
I	NULL
P.	NULL
Surel	NULL
,	NULL
N.	NULL
Faulhaber	NULL
,	NULL
C.	NULL
Frommel	NULL
,	NULL
J.	NULL
Schneider-Mergener	NULL
,	NULL
C.	NULL
Schonemann	NULL
,	NULL
P.	NULL
Reinke	NULL
,	NULL
and	NULL
H.	NULL
D.	NULL
Volk	NULL
.	NULL

1999	NULL
.	NULL

Target	NULL
structures	NULL
of	NULL
the	NULL
CD8	NULL
*-T-cell	NULL
response	NULL
to	NULL
human	NULL
cytomegalovirus	NULL
:	NULL
the	NULL
72-kilodalton	NULL
major	NULL
immediate-carly	NULL
protein	NULL
revisited	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

73:8179	NULL
.	NULL

Kovats	NULL
,	NULL
S.	NULL
,	NULL
G.	NULL
T.	NULL
Nepom	NULL
,	NULL
M.	NULL
Coleman	NULL
,	NULL
B.	NULL
Nepom	NULL
,	NULL
W.	NULL
W.	NULL
Kwok	NULL
,	NULL
and	NULL
J.	NULL
S.	NULL
Blum	NULL
.	NULL

1995	NULL
.	NULL

Deficient	NULL
antigen-presenting	NULL
cell	NULL
function	NULL
in	NULL
multiple	NULL
genetic	NULL
complemen-tation	NULL
groups	NULL
of	NULL
type	NULL
II	NULL
bare	NULL
lymphocyte	NULL
syndrome	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

96:217	NULL
.	NULL

Ettinger	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
and	NULL
W.	NULL
W.	NULL
Kwok	NULL
.	NULL

1998	NULL
.	NULL

A	NULL
peptide	NULL
binding	NULL
motif	NULL
for	NULL
HLA-DQA1*0102/DQB1*0602	NULL
,	NULL
the	NULL
class	NULL
II	NULL
MHC	NULL
molecule	NULL
associated	NULL
with	NULL
dominant	NULL
protection	NULL
in	NULL
insulin-dependent	NULL
diabetes	NULL
mellitus	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

160:2365	NULL
.	NULL

Brosterhus	NULL
,	NULL
H.	NULL
,	NULL
S.	NULL
Brings	NULL
,	NULL
H.	NULL
Leyendeckers	NULL
,	NULL
R.	NULL
A.	NULL
Manz	NULL
,	NULL
S.	NULL
Miltenyi	NULL
,	NULL
A.	NULL
Radbruch	NULL
,	NULL
M.	NULL
Assenmacher	NULL
,	NULL
and	NULL
J.	NULL
Schmitz	NULL
.	NULL

1999	NULL
.	NULL

Enrichment	NULL
and	NULL
detection	NULL
of	NULL
live	NULL
antigen-specific	NULL
CD4*	NULL
and	NULL
CD8*	NULL
T	NULL
cells	NULL
based	NULL
on	NULL
cytokine	NULL
secretion	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

29:4053	NULL
.	NULL

Sette	NULL
,	NULL
A.	NULL
,	NULL
J.	NULL
Sidney	NULL
,	NULL
C.	NULL
Oseroff	NULL
,	NULL
M.-F.	NULL
del	NULL
Guercio	NULL
,	NULL
S.	NULL
Southwood	NULL
,	NULL
T.	NULL
Arrhenius	NULL
,	NULL
M.	NULL
F.	NULL
Powell	NULL
,	NULL
S.	NULL
M.	NULL
Colon	NULL
,	NULL
F.	NULL
C.	NULL
A.	NULL
Gaeta	NULL
,	NULL
and	NULL
H.	NULL
M.	NULL
Grey	NULL
.	NULL

1993	NULL
.	NULL

HLA-DR4Dw4-binding	NULL
motifs	NULL
illustrate	NULL
the	NULL
biochemical	NULL
basis	NULL
of	NULL
degeneracy	NULL
and	NULL
specificity	NULL
in	NULL
peptide-DR	NULL
interactions	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

151:3163	NULL
.	NULL

Marshall	NULL
,	NULL
K.	NULL
W.	NULL
,	NULL
K.	NULL
J.	NULL
Wilson	NULL
,	NULL
J.	NULL
Liang	NULL
,	NULL
A	NULL
.	NULL

Woods	NULL
,	NULL
D.	NULL
Zaller	NULL
,	NULL
and	NULL
J	NULL
.	NULL

B.	NULL
Rothbard	NULL
.	NULL

1995	NULL
.	NULL

Prediction	NULL
of	NULL
peptide	NULL
affinity	NULL
to	NULL
HLA	NULL
DRB1*0401	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

154:5927	NULL
.	NULL

Rammensee	NULL
,	NULL
H.	NULL
G.	NULL
,	NULL
T.	NULL
Friede	NULL
,	NULL
and	NULL
S.	NULL
Stevanoviic	NULL
.	NULL

1995	NULL
.	NULL

MHC	NULL
ligands	NULL
and	NULL
peptide	NULL
motifs	NULL
:	NULL
first	NULL
listing	NULL
.	NULL

Immunogenetics	NULL
41:178	NULL
.	NULL

Demotz	NULL
,	NULL
S.	NULL
,	NULL
C.	NULL
Barbey	NULL
,	NULL
G.	NULL
Corradin	NULL
,	NULL
A.	NULL
Amoroso	NULL
,	NULL
and	NULL
A.	NULL
Lanzavecchia	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
set	NULL
of	NULL
naturally	NULL
processed	NULL
peptides	NULL
displayed	NULL
by	NULL
DR	NULL
molecules	NULL
is	NULL
tuned	NULL
by	NULL
polymorphism	NULL
of	NULL
residue	NULL
86	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

23:425	NULL
.	NULL

Dessen	NULL
,	NULL
A.	NULL
,	NULL
C.	NULL
M.	NULL
Lawrence	NULL
,	NULL
S.	NULL
Cupo	NULL
,	NULL
D.	NULL
M.	NULL
Zaller	NULL
,	NULL
and	NULL
D.	NULL
C.	NULL
Wiley	NULL
.	NULL

1997	NULL
.	NULL

X-ray	NULL
crystal	NULL
structure	NULL
of	NULL
HLA-DR4	NULL
(	NULL
DRA*0101	NULL
,	NULL
DRB1*0401	NULL
)	NULL
complexed	NULL
with	NULL
a	NULL
peptide	NULL
from	NULL
human	NULL
collagen	NULL
IL	NULL
.	NULL

Immunity	NULL
7:473	NULL
.	NULL

Tan	NULL
,	NULL
L.	NULL
C.	NULL
,	NULL
N.	NULL
Gudgeon	NULL
,	NULL
N.	NULL
E.	NULL
Annels	NULL
,	NULL
P.	NULL
Hansasuta	NULL
,	NULL
C.	NULL
A.	NULL
O'Callaghan	NULL
,	NULL
S.	NULL
Rowland-Jones	NULL
,	NULL
A.	NULL
J.	NULL
McMichael	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
,	NULL
and	NULL
M.	NULL
F.	NULL
Callan	NULL
.	NULL

1999	NULL
.	NULL

A	NULL
re-evaluation	NULL
of	NULL
the	NULL
frequency	NULL
of	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
specific	NULL
for	NULL
EBV	NULL
in	NULL
healthy	NULL
virus	NULL
carriers	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

162:1827	NULL
.	NULL

Rabinowitz	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
M.	NULL
Vrljic	NULL
,	NULL
P.	NULL
M.	NULL
Kasson	NULL
,	NULL
M.	NULL
N.	NULL
Liang	NULL
,	NULL
R.	NULL
Busch	NULL
,	NULL
J.	NULL
J.	NULL
Boniface	NULL
,	NULL
M.	NULL
M.	NULL
Davis	NULL
,	NULL
and	NULL
H.	NULL
M.	NULL
McConnell	NULL
.	NULL

1998	NULL
.	NULL

Formation	NULL
of	NULL
a	NULL
highly	NULL
peptide-recep-tive	NULL
state	NULL
of	NULL
class	NULL
II	NULL
MHC	NULL
.	NULL

Immunity	NULL
9:699	NULL
.	NULL

Cochran	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
T.	NULL
O.	NULL
Cameron	NULL
,	NULL
and	NULL
L.	NULL
J.	NULL
Stern	NULL
.	NULL

2000	NULL
.	NULL

The	NULL
relationship	NULL
of	NULL
MHC-peptide	NULL
binding	NULL
and	NULL
T	NULL
cell	NULL
activation	NULL
probed	NULL
using	NULL
chemically	NULL
defined	NULL
MHC	NULL
class	NULL
II	NULL
oligomers	NULL
.	NULL

Immunity	NULL
12:241	NULL
.	NULL

Kern	NULL
,	NULL
F.	NULL
,	NULL
N.	NULL
Faulhaber	NULL
,	NULL
C.	NULL
Frommel	NULL
,	NULL
E.	NULL
Khatamzas	NULL
,	NULL
S.	NULL
Prosch	NULL
,	NULL
C.	NULL
Schonemann	NULL
,	NULL
I.	NULL
Kretzschmar	NULL
,	NULL
R.	NULL
Volkmer-Engert	NULL
,	NULL
H.	NULL
D.	NULL
Volk	NULL
,	NULL
and	NULL
P.	NULL
Reinke	NULL
.	NULL

2000	NULL
.	NULL

Analysis	NULL
of	NULL
CD8	NULL
T	NULL
cell	NULL
reactivity	NULL
to	NULL
cytomegalovirus	NULL
using	NULL
protein-spanning	NULL
pools	NULL
of	NULL
overlapping	NULL
pentadecapeptides	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

30:1676	NULL
.	NULL

Udaka	NULL
,	NULL
K.	NULL
,	NULL
K.	NULL
H.	NULL
Wicsmiiller	NULL
,	NULL
S.	NULL
Kienle	NULL
,	NULL
S.	NULL
Feiertag	NULL
,	NULL
G.	NULL
Jung	NULL
,	NULL
and	NULL
P.	NULL
Walden	NULL
.	NULL

1996	NULL
.	NULL

Random	NULL
peptide	NULL
libraries	NULL
as	NULL
tools	NULL
in	NULL
basic	NULL
and	NULL
applied	NULL
immunology	NULL
.	NULL

In	NULL
Combinatorial	NULL
Peptide	NULL
and	NULL
Nonpeptide	NULL
Libraries	NULL
.	NULL

G.	NULL
Jung	NULL
,	NULL
ed	NULL
.	NULL

VCH	NULL
Verlagsge-sellschaft	NULL
mbH	NULL
,	NULL
Weinheim	NULL
,	NULL
p.	NULL
349-362	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL

